CURRICULUM VITAE Date
Prepared: November
21, 2004
Name: C. Michael Gibson, M.S.,
M.D.
Office Address: TIMI Study Group
Home Address:
E:Mail: mgibson@perfuse.org FAX: 617-734-7329
Place of Birth:
Education:
1982 B.A.
1984
M.S.
1986 M.D.
Postdoctoral Training:
Internships
and Residencies:
1986-1987 Intern in Medicine, Brigham and Women's
Hospital,
1987-1989 Junior and Senior Resident in Medicine,
Brigham and Women's Hospital,
1989 Chief Medical Resident
Physician, West Roxbury Veterans Administration Hospital, Boston MA, Harvard
Medical School (During three months as a Senior Resident, Brigham and Women’s
Hospital)
1992-1993 Chief Medical Resident Physician,
Brigham and Women's Hospital,
Clinical
and Research Fellowships:
1989-1992 Cardiology Fellow,
Academic Appointments:
7/91-4/95 Instructor in Medicine,
4/95-6/98 Assistant
Professor of Medicine,
11/98-8/99 Professor of Medicine,
9/99-2/01 Associate Professor of Medicine,
2002- Associate Professor of Medicine,
Hospital Appointments:
1989- Founder and Director, PERFUSE
Core Laboratories and
1991-1994 Director, Quantitative Angiographic Core
Laboratory, Invasive Cardiology Section,
1993-1994
Director, Coronary Care Unit,
1993-1994
Associate in Medicine,
1994-1998 Director, Interventional Cardiology, West
Roxbury Veteran's Administration Hospital, Harvard Medical School, Boston MA.
1994-1998 Director, Cardiac Catheterization
Laboratory, West Roxbury Veteran's Administration Hospital, Harvard Medical
School, Boston MA.
1994-1998 Associate Physician,
Brigham and Women's Hospital,
1996-1998 Director, Clinical Trials Unit, West
Roxbury Veteran’s Administration Hospital, Harvard Medical School, Boston MA.
1996-1998 Chief, Cardiovascular Division, West
Roxbury VA Hospital,
1997- Director TIMI Master Database and Coordinating
Center
1998-1999
Director
of Invasive Cardiology,
1998-1999 Director Interventional Cardiology
Fellowship Program,
1998-1999Vice Chairman of Medicine, Clinical
Research,
1999-2000Associate Chief of Cardiology,
1999-2000Chief, Interventional Cardiology,
Feb 2001 Associate in Medicine,
2001- 2002 Director Core Cardiovascular Services, Harvard Clinical Research
Institute
2001-2002 Chief Academic Officer
(CAO), Harvard Clinical Research Institute
2002- Associate Chief of Cardiology and Director of Academic
Affairs,
Major Committee
Assignments:
Hospital:
1992-1993 Intern
selection committee, Brigham and Women's Hospital,
1992-1993 Emergency Room Services Committee,
Brigham and Women's Hospital,
1993-1994 Critical Care Committee,
1993-1994 Quality Assurance Committee,
1993-1994 Patient Care Committee,
1993-1994 Intern selection Committee,
1996
Massachusetts
Peer Review Organization (MASS PRO) reviewer of acute myocardial infarction
processes and outcomes at academic institutions in the
1995-1997 Director Cardiovascular Grand Rounds,
1997 Conscious sedation committee,
1997
Chairman,
Coronary Intermediate Care Unit and Outpatient Cardiac Catheterization
Activation Committee,
1998-1999
Chairman,
Cardiac Catheterization Laboratory Resource Utilization Committee,
1998-1999
Chairman,
Cardiac Catheterization Laboratory Executive Committee,
1998-1999
Directed
committee dedicated to improving Clinical Research at
1. Conceived
and developed a database for tracking the time it takes for trials to be
approved: (time for grants & contracts office to prepare trial budget; time
for Principal Investigator to submit to IRB; time from submission to IRB to
first review; time for PI to resubmit protocol to IRB for re-review; time for
IRB to review protocol again; time for PI to submit all required changes; total
time for IRB approval; time for legal review;
time required for sponsor to sign off on contract; time for
administrative sign off; time for Department/Division sign off. As a
result of all of the above, reduced time required for trials to be enrolling by
one month.
2. Conceived and edited Department of
Medicine Newsletter regarding 38 ongoing Clinical Trials: Changes in
operational policies disseminated; dates and times of educational programs
posted; publications of investigators listed;
new trial every month highlighted; active trials with contact numbers
listed.
3. Renegotiated
cost structure of clinical trials accounting system for entire hospital system
from one that used highly volatile cost-to-charge ratios to one that used
unvarying Medicare costs and stabilized cost accounting system. Conceived and
directed creation of 300 page master list of costs for all tests in hospital
that was accessible to clinical researchers.
4. Conceived
and directed SCORE program (Scholars Concentrating On Research Excellence), a
16 lecture educational program directed at research coordinators, residents,
fellows, and attending physicians designed to educate clinical researchers.
Each participant received a 200 page binder of
curricular materials. Topics included: trial design; statistical methodology
(power, sample size, confidence intervals); site readiness; regulatory issues
(IRB, adverse event reporting); good clinical practices; clinical event
committees, data safety monitoring; database management; statistical analysis software,
including a “how to manual”; techniques in the assessment of cost
effectiveness, quality of life, patient satisfaction; trial management (CRO,
Chairman’s office, Core Lab); the FDA approval process.
5.
Conceived
and directed development of software to track clinical trials monies. Designed
budget sheet which tracked % of monies spent on patient care and compared this
with trial projections to assure that hospital was being reimbursed
appropriately for services and test; tracked number of patients enrolled and
projections of monies owed by sponsors; developed warning systems to identify
investigators who were over budget.
Realized net profit of $172,000.00 in 9 months (annualized profit of
$230,000.00) on revenues of $351,000.00 (annualized revenues of $468,000.00).
1999-2001 Quality Assurance Committee, Cardiac
Catheterization Laboratory,
Academic:
1994-1995 Member TIMI 9B Morbidity and Mortality
Classification Committee
1995-1998 Chairman, Data Safety Monitoring Board
for a trial assessing Transmyocardial Laser Revascularization in inoperable
coronary artery disease.
1996 Member TIMI 11A Morbidity and
Mortality Classification Committee
1996 Ad Hoc Member NHLBI Clinical
Trials Review Committee
1996-1998 Chairman, Data Safety Monitoring Board
for a trial assessing Transmyocardial Laser Revascularization as an adjunct to
Coronary Artery Bypass Grafting
1997-
Director
of TIMI Data Coordinating Center, Creator of Master Database for the TIMI
Studies
2000-
Member,
Board of the National Registry of Myocardial Infarction
2002- Executive Committee of ADVANCENT,
a national congestive heart failure registry
2003-
Executive
Committee, ASSENT 4
2003- Chairman,
Medical Advisory Board, Angel Medical
Professional Societies:
1986 Member American Medical Association
1992
1996
2000
2002 Member
of the AHA Council on Atherosclerosis, Thrombosis, and Vascular Biology
Editorial Boards and
Manuscript Review:
Journals
Editorial Board, Circulation
Editorial Board, Journal of the
Editorial Board, Journal of Thrombosis
and Thrombolysis
Section Editor,
Journal of Critical Pathways
Reviewer, American Journal of Cardiology
Reviewer, American Heart Journal
Reviewer, Cardiac Catheterization and Diagnosis
Internet Publications / Websites
Editor Clinical Trials Section, American
Editorial
Board www.theheart.org
Founder and Editor-in-Chief of www.clinicaltrialresults.org
an online resource for the distribution of clinical trial results.
Founder
and Editor-in-Chief of
www.perfuse.org, a website dedicated to
the distribution of information regarding the analysis of coronary blood flow
Founder,
Editor-in-Chief and webmaster of the www.timi.org,
a website dedicated to the distribution of information regarding the outcomes
of trials in the area of acute coronary syndromes
Founder,
Editor-in-Chief, www.thepvd.org, the
website of the Peripheral Vascular Disease Group, dedicated to the distribution
of educational material regarding peripheral vascular disease.
Editor-in-Chief
of www.ihadaheartattack.com an
informational site for patients
Webmaster
of www.criticalpathways.org and
www.criticalpathwaysincardiology.com
Awards and Honors:
High
School
1978 Ranked first among 225 recipients of
a National Honor Society scholarship from a national applicant field of 36,000
students by the combined committees of the National Honor Society, Educational
Testing Service and the Secondary School Principal's Association.
Class Valedictorian
Four sport varsity letterman.
Special National Merit Scholar
College
1982 graduated Phi Beta Kappa
1982 Graduated with General and Special
Honors as an undergraduate student
Associate membership in Sigma Xi Research
Society
Three year varsity
letterman in football.
Starting halfback second year of college
Rhodes scholarship state finalist
Dean's List for 4 years
1984 National Young Investigator Award in
Orthopedic Surgery
1986 Graduated Alpha Omega Alpha
1986 Honors graduate, Pritzker School of
Medicine University of
Post
Graduate
1993-1994 Julian and Eunice Cohen Scholar
in Medicine, Brigham and Women's Hospital,
2002-
Strathmore’s Who’s Who, Selected a lifetime member
Part II: Research,
Teaching, and Clinical Contributions
Narrative report of
Research, Teaching, and Clinical Contributions
Dr. Gibson is founder and director of PERFUSE
(Percutaneous/Pharmacologic Endoluminal Revascularization For Unstable
Syndromes Evaluation), an academic research organization. Dr. Gibson’s work has largely focused on the
development of the statistical and angiographic methodologies to investigate
the pathophysiology of coronary artery disease and the efficacy of therapeutic
modalities. He directs the Angiographic
Core Laboratory for a wide variety of studies including acute MI studies, large
scale international interventional trials, numerous new device trials,
peripheral interventional trials, angiogenesis trials (VEGF), imaging modality
studies, managed care analyses for HCFA, and atherosclerosis regression trials
such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP)
and PEARL (role of estrogens in restenosis).
In the field of atherosclerosis, Dr.
Gibson determined that the multiple blockages within a patient progress in
their severity at independent rates, and he along with Dr. Bernard Rosner
developed and validated the statistical methodology that is used to analyze
angiographic data from many atherosclerosis regression trials. Likewise, in the field of interventional
cardiology, Dr. Gibson demonstrated that when multiple blockages within a
patient are dilated, the risk of reblockage or restenosis is independent among
all the lesions. This provides the
methodological basis for all interventional trials analyzing restenosis data on
a per lesion basis rather than on a per patient basis.
Dr. Gibson developed the TIMI
(Thrombolysis In Myocardial Infarction) frame count (CTFC) in which the number
of cineframes for dye to reach standardized distal landmarks is counted as an
index of coronary blood flow. This
measure is now the primary endpoint in some acute MI trials. Dr. Gibson also
developed the TIMI myocardial perfusion grade (a measure of microvascular
perfusion). In this method, the rate of
dye entry and exit from the heart muscle is assessed visually. The TIMI frame
count and the TIMI myocardial perfusion grade are both multivariate predictors
of mortality in acute MI. The thrust of
Dr. Gibson’s current research lies in developing computer techniques to more
precisely quantitate the flow of dye into the heart muscle to quantitate the
perfusion of the myocardium at the microvascular or tissue level.
The TIMI study group has 15 years in the
conduct of trials in acute coronary syndromes. Over the past 3 years Dr. Gibson
has coordinated substudy queries from TIMI trials 1 to 14. Dr. Gibson directed the creation of a master
database that unifies data from multiple TIMI trials.
Dr. Gibson is an active interventional
cardiologist and has served as Chief of Interventional Cardiology in several
catheterization laboratories (West Roxbury VA, Allegheny General, University
California San Francisco) and has served as Director of the Coronary Care Unit
at
Research Funding
Information:
Past:
1998-93
National
Institute of Health, Principal Investigator Quantitative Angiographic Core Laboratory,
Harvard Atherosclerosis Reversibility Project, Lipid Lowering Trial
1998-93
National
Institute of Health, Principal Investigator Quantitative Angiographic Core Laboratory, Harvard Atherosclerosis
Reversibility Project, Fish Oil Trial
1991-93
Smith
Kline Beecham, Principal Investigator Quantitative Angiographic Core Laboratory
Thrombolysis
in Myocardial Infarction Phase 4 (TIMI 4)
1993-94
Ciba
Geigy, Principal Investigator,
Thrombolysis
in Myocardial Infarction Phase 9A (TIMI 9A)
1993-94 Ciba Geigy, Principal Investigator
Quantitative Angiographic Core Laboratory Thrombolysis In
Myocardial Infarction Phase 9A trial (TIMI 9A)
1993-94 Biogen Inc., Principal Investigator,
Beth Israel Hospital and subsequently West Roxbury Veteran's Administration,
Harvard Medical School
A
prospective randomized trial comparing the efficacy of hirulog versus heparin
in preventing post PTCA reocclusion
1993-94Otsuka Pharmaceutical, Principal
Investigator,
A
randomized trial comparing the efficacy of Vesniranone to Dobutamine
1993-94Merck Dupont, Principal Investigator,
1993-94
Biogen
Inc., Principal Investigator,
1994-95
Health
Care Finance Administration (HCFA), Principal Investigator Quantitative
Angiographic Core Laboratory
A Comparative Analysis of Disease Extent
Prior to Coronary Artery Bypass Grafting
1995-96
Rhone-Poulenc
Rorer, Principal Investigator,
Thrombolysis In
Myocardial Infarction Phase 11 trial (TIMI 11A) of Enoxaparin
1995-97
Genentech,
Inc., Principal Investigator,
Thrombolysis in Myocardial Infarction
Phase 12 trial (TIMI 12) a phase 2 trial of Ro 48-3657 (a new oral IIb/IIIa
platelet receptor antagonist)
1995-98
Genentech,
Inc., Principal Investigator Quantitative Angiographic Core Laboratory
Thrombolysis In
Myocardial Infarction Phase 10 pilot trial (TIMI 10A)
1995-97
Merck
& Co., Inc., Co-Principal Investigator,
MK-383 in the Treatment of Unstable
Angina
1995-97 Merck & Co., Inc., Principal
Investigator Quantitative Angiographic Laboratory MK-383 restenosis trial in patients
undergoing conventional PTCA or Atherectomy (RESTORE)
1995-97
Merck
& Co. Inc., Principal Investigator, West Roxbury Veterans
Administration Hospital, Harvard Medical
School, MK-383 in Patients Undergoing Conventional PTCA or Atherectomy
(RESTORE)
1995-97
National
Institute of Health, Principal Investigator,
Triggers of acute MI study
1995-97
Schneider
Inc., Principal Investigator Angiographic and Electrocardiographic Core
Laboratories
Comparative evaluation of the FreeFlow
catheter
1996-98
Guidant
Corporation, Principal Investigator Quantitative Angiographic Core Laboratory
Medium sized vessel atherectomy trial
1996-98
Genentech,
Inc., Principal Investigator Quantitative Core Laboratory
Thrombolysis In
Myocardial Infarction Phase 10 B trial of TNK (TIMI 10B)
1996-98
Parke
Davis, Principal Investigator,
AVERT trial of Atorvastatin
1996-98 Schneider Inc., Principal
Investigator Quantitative Angiographic Core Laboratory WALLSTENT Femoral Endoprosthesis and
the Unistep Plus Delivery System
1996-98
Schneider
Inc., Principal Investigator Quantitative Angiographic Core Laboratory
WALLGRAFT Endoprosthesis with PET
Covering and the Unistep LS Delivery System
1997-98
Rhone-Poulenc
Rorer / Aventis Pharmaceuticals, Principal Investigator,
Thrombolysis in Myocardial Infarction
Phase 11B Trial of Enoxaparin (TIMI 11B)
1997 Angiostent Inc., Principal
Investigator Quantitative Angiographic of the ANGIOSTENT Trial
1997-98
Genentech,
Inc., Principal Investigator Angiographic Core Laboratory
Phase 1B trial of rh-VEGF
1997-98 Bard, Principal Investigator, West
Roxbury Veterans Administration Hospital ProntoFlex Perfusion balloon Trial
1998 Bard, Principal Investigator of
the BARD study of geometry of bifurcation lesions
1998-99
Vascular
Therapeutics Inc., Principal Investigator of the quantitative angiographic
analysis, data entry and management, of the angiographic core laboratory
Phase II trial of Vasoflux (The VITAL
Trial)
1998-1999 Sonus Pharmaceuticals, Principal
Investigator of the quantitative angiographic analysis, data entry and
management, of the angiographic core laboratory
Phase III, Multicenter, Single Blind
Study Comparing Non-Enhanced
Stress Echocardiography in the Visualization of Wall Motion and
the Diagnosis of Coronary Artery Disease (ECHOGEN trial)
1998-2000 Centocor and Eli Lilly, Principal
Investigator of the quantitative angiographic analysis, data entry and
management, of the angiographic core laboratory Thrombolysis In Myocardial
Infarction Phase 14 trial of ReoPro in acute MI (TIMI 14)
1998-2000 Centocor and Eli Lilly, Principal Investigator rendering the final readings for the pooled data from the SPEED and TIMI 14 trials of ReoPro plus RPA in acute MI
1998-2000 Merck & Co., Inc., Principal Investigator of the quantitative angiographic analysis, data entry and management, of the angiographic core laboratory
TIMI 18 TACTICS trial
1998-2000 Genentech Inc., Principal Investigator of the quantitative angiographic analysis, data entry and management, of the angiographic core laboratory
LIMIT trial of rhuMAb CD18 as an adjunct to thrombolysis (an antibody directed against neutrophils)
1998-1999 Genentech Inc., Principal Investigator of the angiographic core laboratory
Phase 2 trial of rh-VEGF (VIVA Trial)
1999-2000 AstraZeneca, Principal Investigator of the quantitative angiographic analysis, data entry and management of the angiographic data
An open study, with blinded endpoint assessment, to assess the safety, tolerability and the effect on coronary artery patency of intravenous AR-C69931MX as both monotherapy and adjunct to Activase in patients with ST-elevation myocardial infarction (the STEP AMI trial)
1999-2001 Merck & Co., Inc., Principal Investigator of the quantitative angiographic analysis, data entry and management of angiographic data
Fibrinolytic and AggrastatR ST-elevation Resolution Trial (FASTER trial)
1999-2001 Aventis, Principal Investigator of the
quantitative angiographic analysis, data entry and management of angiographic
data
Enoxaparin and TNK-tPA
with or without GPIIb/IIIa inhibitors as reperfusion strategy in ST-elevation
myocardial infarction (the ENTIRE trial)
1999-2001 COR Therapeutics, Principal Investigator
of the quantitative angiographic analysis, data entry and management of angiographic
data
Integrilin and TNK in Acute Myocardial
infarction (the INTEGRITI trial)
2000-2001 COR Therapeutics, Principal Investigator
of the quantitative angiographic analysis
Enhanced suppression of the platelet
GPIIb/IIIa receptor with IntegrilinTM Therapy (ESPRIT Trial)
2000-2001 NIH, Principal Investigator Quantitative Angiographic Core Laboratory
PEARL study of estrogens in restenosis
1996-2003 Schneider Inc. (now Boston Scientific),
Principal Investigator of the quantitative angiographic analysis, data entry
and management, of the angiographic core laboratory: Wallstent in peripheral
vessels
1996-2003
Schneider
Inc. (now Boston Scientific), Principal Investigator of the quantitative
angiographic analysis, data entry and management, of the angiographic core
laboratory: Wallstent in central vessels
2002 Pfizer Pharmaceuticals, Principal Investigator of the
quantitative angiographic analysis, data entry and management of angiographic
data of a trial to assess presence
and magnitude of coronary vasoconstriction associated with a novel migraine compound (Eletriptan)
Current
2002-
Millenium Pharmaceutical, Principal
Investigator of ADVANCE MI. A 5,500
patient international multicenter trial to assess the efficacy of eptifibatide
administered in the emergency room versus eptifibatide in combination with half
dose TNK among patients undergoing PCI in the management of acute MI
2002- British Biotech, Principal
Investigator, TIMI Angiographic Core Laboratory, TIMI 34. An international
multicenter dose escalation trial of the new thrombolytic agent BB10153
(activated only by clot bound thrombin)
2003- Millenium Pharmaceuticals, Principal
Investigator of TITAN TIMI 31. An international multicenter trial to assess the
efficacy of eptifibatide administered in the emergency room versus the cardiac
catheterization laboratory in the management of acute MI
2002- Millenium Pharmaceuticals,
Principal Investigator, TIMI Angiographic Core Laboratory and TIMI Data
Coordinating Center, TITAN TIMI 31. An international multicenter trial to
assess the efficacy of eptifibatide administered in the emergency room versus
the cardiac catheterization laboratory in the management of acute MI
2003- Bristal Meyers Squibb, Principal
Investigator, TIMI angiographic core laboratory, CLARITY. A 3,000 patient
international multicenter trial to assess the efficacy of clopidogrel in
improving patency following thrombolytic administration
2003- Millenium Pharmaceuticals, Principal
Investigator, TIMI Angiographic Core Laboratory, ADVANCE MI. A 5,500 patient
international multicenter trial to assess the efficacy of eptifibatide
administered in the emergency room versus the versus
eptifibatide in combination with half dose TNK among patients undergoing PCI in
the management of acute MI.
2002- Corgentech, Principal
Investigator of the quantitative angiographic analysis, data entry and
management, of the angiographic core laboratory, PREVENT 4. A 2,200 patient
trial of a novel agent to reduce saphenous vein graft occlusion
2001- TIMI 3 Systems, Principal
Investigator of the quantitative angiographic analysis, data entry and
management, of the angiographic core laboratory, the PLUS study. An
international multicenter trial evaluating the efficacy of transcutaneous
ultrasound to facilitate thrombolysis
2002- Point Biomedical, Principal
Investigator of the quantitative angiographic analysis, data entry and
management, of the angiographic core laboratory of a trial investigating the
efficacy of a novel myocardial contrast agent
2003- Eli Lilly, Principal Investigator
of the quantitative angiographic analysis, data entry and management, of the
angiographic core laboratory, the SWEDES trial of primary angioplasty
2003- ActivBiotics, Principal
Investigator of CAROTID, a multicenter trial to assess the efficacy of a novel
antibiotic (rifalazil) in the penetration of atherosclerotic plaque.
2002- St. Judes Medical, Principal
Investigator of the quantitative angiographic analysis, data entry and
management, of the angiographic core laboratory, the St. Judes Trial of a novel
proximal anastomotic connector device for saphenous vein grafts
2002- St. Judes Medical, Principal
Investigator of the quantitative angiographic analysis, data entry and
management, of the angiographic core laboratory, the St. Judes Trial of a novel
distal anastomotic connector device for saphenous vein grafts
2003- TIMI 3 Systems, Principal
Investigator of the quantitative angiographic analysis, data entry and
management, of the angiographic core laboratory, a single center study at
Major Research Interests:
Founder and
Director of the PERFUSE Core
Laboratories and Data Coordinating Center
(Percutaneous/Pharmacologic Endoluminal Revascularization For Unstable Syndromes Evaluation)
1. Atherosclerosis Regression and
Prevention
Director of the quantitative angiographic
analysis of the NIH sponsored Harvard Atherosclerosis Reversibility Project (HARP) Lipid
Lowering Trial
Director of the quantitative angiographic
analysis of the NIH sponsored Harvard Atherosclerosis Reversibility Project (HARP) Fish Oil
Trial
Principal Investigator West Roxbury VA
Hospital,
2. Thrombolysis and Unstable Angina
Director of the quantitative angiographic
analysis of the Thrombolysis In Myocardial Infarction
Phase 4 trial (TIMI 4)
Director of the quantitative angiographic
analysis of the Thrombolysis In Myocardial Infarction
Phase 9A trial (TIMI 9A)
Principal Investigator,
Member TIMI 9B Morbidity and Mortality
Classification Committee
Director of the quantitative angiographic
analysis of the Thrombolysis In Myocardial Infarction
Phase 10 pilot trial (TIMI 10A)
Director of the quantitative angiographic
analysis of the Thrombolysis In Myocardial Infarction
Phase 10 B trial (TIMI 10B) of TNK
Principal Investigator,
Member TIMI 11A Morbidity and Mortality
Classification Committee
Principal Investigator,
Principal Investigator,
Principal Investigator,
Collaborated as the Angiographic Core
Laboratory for the Coumadin Aspirin Reinfarction Study (CARS)
Principal Investigator,
Co-Principal Investigator,
Principal Investigator,
Director of the quantitative angiographic
analysis of the Thrombolysis In Myocardial Infarction
Phase 14A trial (TIMI 14) of ReoPro in acute MI
Principal Investigator of the
angiographic core laboratory for an International Multicenter 350 patient phase
II trial of Vasoflux (VITAL)
Principal Investigator of the
angiographic core laboratory for the LIMIT trial, an international multicenter
500 patient trial of rhuMAb CD18 as an adjunct to thrombolysis (an antibody
directed against neutrophils)
Principal Investigator of the
angiographic core laboratory for an international multicenter trial of low dose
RPA plus full dose ReoPro in acute MI (SPEED Trial: Strategies
for Patency Enhancement in the Emergency Department). Rendered
final angiographic core laboratory readings on data to be pooled with the TIMI
14 trial.
Principal Investigator of the
angiographic core laboratory for an international multicenter trial entitled An
open study, with blinded endpoint assessment, to assess the safety,
tolerability and the effect on coronary artery patency of intravenous
AR-C69931MX as both monotherapy and adjunct to Activase in patients with
ST-elevation myocardial infarction (STEP AMI)
Principal Investigator of the
angiographic core laboratory for an international multicenter trial of
tirofiban plus low dose TNK in patients with ST-elevation myocardial infarction
(FASTER trial)
Principal Investigator of the
angiographic core laboratory for an international multicenter trial of Enoxaperin
plus low dose TNK in patients with ST-elevation myocardial infarction (the
ENTIRE trial)
Principal Investigator of the
angiographic core laboratory for an international multicenter trial of
eptifibatide plus low dose TNK in patients with ST-elevation myocardial
infarction (the INTEGRITI trial)
Principal Investigator
of ADVANCE MI. A 5,500 patient international multicenter
trial to assess the efficacy of eptifibatide administered in the emergency room
versus eptifibatide in combination with half dose TNK among patients undergoing
PCI in the management of acute MI
Executive Committee of
ASSENT 4. A 4,000 patient international multicenter
trial to assess the efficacy of TNK plus enoxaparin in the emergency room
versus conventional unfractionated heparin among patients undergoing PCI in the
management of acute MI
Principal Investigator
of TIMI 34. An
international multicenter dose escalation trial of the new thrombolytic agent
BB10153 (activated only by clot bound thrombin)
Principal Investigator
of TITAN TIMI 31. An
international multicenter trial to assess the efficacy of eptifibatide
administered in the emergency room versus the cardiac catheterization
laboratory in the management of acute MI
Principal Investigator of an
international multicenter trial of PARs inhibition in the setting of acute MI
Principle Investigator
of an international multicenter trial of p-selectin inhibition in the
management of patients with unstable angina Principal Investigator, TIMI
angiographic core laboratory, CLARITY. A 2,200 patient international multicenter trial to assess
the efficacy of clopidogrel in improving patency following thrombolytic
administration
Principal Investigator, TIMI Angiographic
Core Laboratory, TIMI 34. An international multicenter dose escalation trial of
the new thrombolytic agent BB10153
Principal Investigator, TIMI Angiographic Core Laboratory,
ADVANCE MI. A 5,500 patient international multicenter trial to assess the
efficacy of eptifibatide administered in the emergency room versus the versus eptifibatide in combination with half dose TNK
among patients undergoing PCI in the management of acute MI. This is the
largest angiographic acute MI trial performed to date
Principal Investigator,
TIMI Angiographic Core Laboratory, and Director of TIMI Data Coordinating
Center of TITAN TIMI 31.
An international multicenter trial to assess the efficacy of eptifibatide
administered in the emergency room versus the cardiac catheterization
laboratory in the management of acute MI
Principal Investigator
of the quantitative angiographic analysis, data entry and management, of the
angiographic core laboratory, the PLUS study. An international multicenter trial
evaluating the efficacy of transcutaneous ultrasound to facilitate thrombolysis
Principal Investigator of the
quantitative angiographic analysis, data entry and management, of the
angiographic core laboratory of a trial investigating the efficacy of a novel
myocardial contrast agent (Point Biomedical)
3.
Interventional Cardiology
Principal Investigator of the
Angiographic Core Laboratory for the International 2,100 patient MK-383
restenosis trial in patients undergoing conventional PTCA or Atherectomy
(RESTORE)
Principal Investigator,
Principal Investigator,
Principal Investigator, West Roxbury
Veterans Administration Hospital,
Harvard Medical School, Veterans Administration Cooperative Trial
Comparing Coronary Artery Bypass Grafting to PTCA in patients with Unstable
Angina (AWESOME trial)
Principal Investigator
of the quantitative angiographic analysis for a comparative evaluation of the
Free Flow catheter (Schneider Inc.)
Principal Investigator of the
quantitative angiographic analysis of the DVI intermediate sized vessel
atherectomy trial (IVAT)
Principal Investigator of the
quantitative angiographic analysis of the Schneider WALLSTENT in peripheral
vessels
Principal Investigator of the
quantitative angiographic analysis of the Schneider WALLSTENT in central
vessels
Principal Investigator of the
quantitative angiographic analysis of the WALLSTENT Femoral Endoprosthesis and
the Unistep Plus Delivery System
Principal
Investigator of the quantitative angiographic analysis of WALLGRAFT
Endoprosthesis
with PET Covering and the Unistep LS Delivery System
Principal Investigator,
Principal
Investigator of the quantitative angiographic analysis of the
ANGIOSTENT
Trial
Principal Investigator of the
quantitative angiographic analysis of the TACTICS-TIMI 18 trial comparing
conservative versus interventional strategies in patients with UA/NQWMI
Principal Investigator of the BARD study
of geometry of bifurcation lesions
Principal Investigator of the
quantitative angiographic analysis of the ESPRIT trial
Principal Investigator of the
quantitative angiographic analysis of the NIH-sponsored
Principal Investigator of the
quantitative angiographic analysis of the Percusurge device, Swiss experience
Principal
Investigator of the quantitative angiographic analysis of a study to examine
the predictors of subacute stent thrombosis
Co-Investigator, Tenax Stent registry
Co-Investigator TAXUS IV
Co-Investigator in the JO-Med stent registry
Co-Investigator in the REPLACE 2 Trial
Principal Investigator
of the quantitative angiographic analysis, data entry and management, of the
angiographic core laboratory, the SWEDES trial of primary angioplasty.
4. Angiogenesis
Principal Investigator of the
angiographic core laboratory for the phase 1B trial of rh-VEGF
Principal Investigator of the
angiographic core laboratory for the phase 2 trial of rh-VEGF
5. Saphenou Vein Graft Disease
Principal Investigator of the
quantitative angiographic analysis, data entry and management, of the
angiographic core laboratory, the St. Judes Trial of a novel proximal
anastomotic connector device for saphenous vein grafts
Principal Investigator of the
quantitative angiographic analysis, data entry and management, of the
angiographic core laboratory, the St. Judes Trial of a novel proximal
anastomotic connector device for saphenous vein grafts
Principal Investigator
of the quantitative angiographic analysis, data entry and management, of the
angiographic core laboratory, PREVENT 4. A 2,200 patient trial of a novel agent to reduce saphenous
vein graft occlusion
6. Congestive Heart Failure
Principal Investigator,
7. Quantitative Angiography
Director, Quantitative Angiographic Core
Laboratory, West Roxbury Veteran's Administration, Harvard Medical School, for the Comparative
Analysis of Disease Extent Prior to Coronary Artery Bypass Grafting, sponsored
by the Health Care Finance Administration, (HCFA)
Director, Quantitative Angiographic Core
Laboratory, Phase II Feasibility Study of the Safety and Efficacy of Coronary
Magnetic Resonance Angiographic (CMRA) Imaging with MS-325 (a comparison of MRI
and angiography)
Director, Quantitative Angiographic Core
Laboratory, Phase III, Multicenter, Single Blind Study Comparing Non-Enhanced
versus enhanced Stress Echocardiography in the Visualization of Wall Motion and
the Diagnosis of Coronary Artery Disease (the ECHOGEN trial)
8. Electrocardiography:
Principal Investigator of the
electrocardiographic core laboratory for the Schneider FreeFlowTM
perfusion balloon trial
Directed EKG analysis and substudies from
TIMI 10A
Directed EKG analysis and substudies from
TIMI 10B
9. Data Coordination:
Direct acquisition and coordination of
all cleaned data from clinical research organizations as it pertains to the
following TIMI Studies (Thrombolysis In Myocardial
Infarction) performed to date:
TIMI 1: Thrombolytic therapy with
tPA vs SK
TIMI 3A: Thrombolytic therapy versus
placebo on lesion severity in unstable angina/non-Q wave MI
TIMI 3B: 1. Thrombolytic therapy
versus placebo therapy in unstable angina/non-Q wave MI
2. Early invasive versus early
conservative strategy in unstable angina/non-Q wave MI
TIMI 3
Registry: Clinical profile and
outcomes of 3,316 patients with unstable angina and non-Q wave MI
TIMI 4: 382 patient trial of tPA versus APSAC versus Combination therapy in Acute MI
TIMI 5: 246 patient trial of
Hirudin versus Heparin in Acute MI
TIMI 6: 193 patient trial of
Hirudin with Streptokinase in Acute MI
TIMI 7: 410 patient trial of
Hirulog in Unstable Angina
TIMI 8: Hirulog versus Heparin in
Unstable Angina and Non-Q Wave MI
TIMI 9A: Hirudin versus Heparin with
Thrombolysis in Acute MI
TIMI 9B: 3000 patient trial of
Hirudin versus Heparin with Thrombolysis in Acute MI
TIMI 10A: 113 patient
Dose Escalation Study of TNK-tPA
TIMI 10B: 880 patient trial of TNK-tPA
versus front loaded tPA in Acute MI
TIMI 11A: Enoxaperin in Unstable Angina
TIMI 11B: Enoxaperin in Unstable Angina
TIMI 12: TIMI 12, a phase 2 Trial of
Ro 48-3657 (oral IIb/IIIa platelet receptor antagonist)
TIMI 14: ReoPro alone versus ReoPro +
tPA versus tPA alone versus ReoPro + SK in Acute MI
TIMI 18: (TACTICS) Comparison of
conservative versus interventional strategies in patients with UA/NQWMI
Assist in the data coordination and
perform data analysis for the trials of Transmyocardial Laser Revascularization
(TMR)(PLC Inc.)
TMR vs Medical Management Trial
Data entry, management and analysis of
angiographic data from the following interventional trials
Database development and data management
of angiographic data for the Pfizer trial of coronary vascular responsiveness
during administration of the 5HT1B/1D-receptor agonists, eletriptan (IV) versus
sumatriptan (SC) in patients with angina
Database development and data management
of echocardiographic data for the H2275n trial comparing the safety and efficacy of adriamycin
and cyclophosphamide followed by taxol to that of adriamycin and
cyclophosphamide followed by taxol plus in node-positive breast cancer patients
Database development and data management
of angiographic data for the clinical trial of the PercuSurge device, a distal
embolization protection device, in patients with acute MI undergoing stenting
Database development and data management
of angiographic data for the ESPRIT trial (Enhanced Suppression of the Platelet
IIb/IIIa Receptor with Integrilin Therapy) in patients undergoing urgent or
elective PCI with stent implantation
Data entry and management of angiographic
data for the international RESTORE study of 2,100 patients
Data entry and
management of angiographic data for the FreeFlow catheter trial (Schneider
Inc.)
Data entry and management of angiographic
data for the DVI intermediate sized vessel atherectomy trial (IVAT)
Data entry and management of angiographic
data for the Schneider WALLSTENT in peripheral vessels
Data entry and management of angiographic
data for the Schneider WALLSTENT in central vessels
Data entry and management of angiographic
data for the WALLSTENT Femoral Endoprosthesis and the Unistep Plus Delivery System
Data entry
and management of angiographic data for the WALLGRAFT
Endoprosthesis
with PET Covering and the Unistep LS Delivery System
Data entry and management of angiographic
data for the ANGIOSTENT Trial
Data entry and management of angiographic
data for the TACTICS-TIMI 18 trial
Data entry and management of angiographic
data of the quantitative angiographic analysis of the Percusurge device
Data entry and management of angiographic
data of the quantitative angiographic analysis of a study to examine the
predictors of subacute stent thrombosis
Data
entry and management of angiographic data from the following thrombolytic
trials:
Data entry and management of angiographic
data from TIMI 10A and TIMI 10B trials of TNK in Acute MI
Data entry and management of angiographic
data from TIMI 14, a trial of ReoPro alone versus ReoPro + tPA
versus tPA alone versus ReoPro + SK in Acute MI
Data entry and management of angiographic
data from an International Multicenter 350 patient phase II trial of Vasoflux
(an antithrombin), sponsored by Vascular Therapeutics Inc. (The VITAL trial)
Data entry and management of angiographic
data from the trial of rhuMAb CD18 as an adjunct to thrombolysis (an antibody
directed against neutrophils)
Data entry and management of angiographic
data from the international multicenter trial of low dose RPA plus full dose
ReoPro in acute MI (SPEED Trial: Strategies for
Patency Enhancement in the Emergency Department). Rendered
final angiographic core laboratory readings on data to be pooled with the TIMI
14 trial.
Data entry and management of angiographic
data from an international multicenter trial entitled An
open study, with blinded endpoint assessment, to assess the safety, tolerability
and the effect on coronary artery patency of intravenous AR-C69931MX as both
monotherapy and adjunct to Activase in patients with ST-elevation myocardial
infarction (STEP AMI)
Data entry and management of angiographic
data from an international multicenter trial of tirofiban plus low dose TNK in
patients with ST-elevation myocardial infarction (TNT trial)
Data entry and management of angiographic
data from an international multicenter trial of Enoxaperin plus low dose TNK in
patients with ST-elevation myocardial infarction (the ENTIRE trial)
Data entry and management of angiographic
data from an international multicenter trial of eptifibatide plus low dose TNK
in patients with ST-elevation myocardial infarction
9.
Transmyocardial and Percutaneous Laser Revascularization
Protocol development, case report design,
analysis of outcomes, drug dosing and nuclear data in TMR trials
Chairman, Data Safety Monitoring Board
for a trial assessing Transmyocardial Laser Revascularization in inoperable
coronary artery disease
Chairman, Data Safety Monitoring Board
for a trial assessing Transmyocardial Laser Revascularization as an adjunct to
Coronary Artery Bypass Grafting
10.
Animal laboratory research
Schneider FreeFlowTM Perfusion
Balloon evaluation
Schneider WallstentTM studies
Assessment of a
percutaneous myocardial revascularization (PMR) CO2 laser with PLC
Inc.
Report of Teaching
Local
Contributions
1981 Teaching Assistant, Division of Biological
Sciences,
1989 Responsible for providing
lectures biweekly to Harvard Medical Students as Chief Medical Resident at the
1992-1993 Responsible for providing lectures
biweekly to Harvard Medical Students as Chief Medical Resident at the Brigham
and Women=s Hospital
1993-1994 Acute Cardiac Care Elective, Course
Director, Harvard medical School (course # ME502M.1b)
1995: Human systems course, section on
cardiac imaging,
1998-1999: Conceived and directed SCORE program
(Scholars Concentrating On Research Excellence), a 16
lecture educational program directed at research coordinators, residents,
fellows, and attending physicians designed to educate clinical researchers.
Each participant received a 200 page binder of
curricular materials. Topics included: trial design; statistical methodology
(power, sample size, confidence intervals); site readiness; regulatory issues
(IRB, adverse event reporting); good clinical practices; clinical event
committees, data safety monitoring; database management; statistical analysis software,
including a “how to manual”; techniques in the assessment of cost
effectiveness, quality of life, patient satisfaction; trial management (CRO, Chairman’s
office, Core Lab); the FDA approval process.
Regional,
National, and International Contributions
1993-1994 Medical or Cardiology Grand Rounds at 7
hospitals, Chaired 5th International Symposium on Coronary Arteriography,
Session on Regression/Progression of Atherosclerotic Disease, Rotterdam
1995 Invited lectures (Medical or
Cardiology Grand Rounds, Symposia) at 10 hospitals, Chaired the "Meet the
Experts session on Quantitative Angiography",
1996 Invited lectures (Medical or
Cardiology Grand Rounds, Symposia) at 18 hospitals or meetings
1997
Invited
lectures (Medical or Cardiology Grand Rounds, Symposia) at 22 hospitals or
meetings, Directed National Symposium on Intervention in Acute Coronary
Syndromes
1998
Chairman
of AHA How to Session on the TIMI Frame Count, Invited lectures (Medical or
Cardiology Grand Rounds, Symposia) at 20 hospitals or meeting
1999
Invited
Lectures (Medical or Cardiology Grand Rounds, Symposia) at 15 hospitals or
meetings
2000 Invited Lectures (Medical or
Cardiology Grand Rounds, Symposia) at 30 hospitals or meetings
Scientific Sessions Chaired
1.
5th International Symposium on Coronary Arteriography, Session on
Regression/Progression of Atherosclerotic Disease,
2.Meet the Experts session on Quantitative
Angiography,
3.
Intervention in Acute Coronary Syndromes,
4. AHA How to Session on the TIMI Frame
Count, 1998.
5. Co chaired “Biotechnology in Cardiovascular Medicine Current and Future Innovations” with Douglas Weaver, AHA satellite symposium 1998.
6. Co chair of “Biotechnology in Cardiovascular Medicine Current and Future Innovations” with Douglas Weaver, AHA satellite symposium 1999.
7. Co chair of “Biotechnology in Cardiovascular Medicine Current and Future Innovations” with Douglas Weaver, AHA satellite symposium 2000.
8. Chairman of AHA How to Symposium on the assessment of the coronary microvasculature, 2000
9. Co chair of “Biotechnology in Cardiovascular Medicine Current and Future Innovations” with Douglas Weaver, AHA satellite symposium 2001.
Report of Clinical
Activities
1993-1994 Attending Physician, Coronary Care Unit,
Beth Israel Hospital, Harvard Medical School, Boston MA
1993-1994 Attending Physician, Interventional
Cardiology Service,
1993-1994 Attending Physician, Cardiac
Catheterization Laboratory,
1994-1998 Attending Physician, Cardiac
Catheterization Laboratory, West Roxbury Veteran's Administration Hospital,
Harvard Medical School, Boston MA
1994-1998 Attending Physician,
Cardiac Catheterization Laboratory, Brigham and Women's Hospital,
1998-1999
Attending
Physician,
1999-2001Attending Physician,
2001- Attending Physician, Interventional
Cardiology Service,
Part III: Bibliography
Original Articles
1. Gibson CM, Gurney CW, Simmons EL, Gaston EO.
Cyclic erythropoiesis in the Sl/Sld mouse. Experimental Hematology 1984; 12:343-348.
2. Gibson CM, Gurney CW, Simmons EL, Gaston EO.
Further studies of cyclic erythropoiesis in mice. Experimental Hematology 1985; 13:855-860.
3. Gibson CM, Reider B, Mikosz R, Andriacchi T.
Analysis of the Mueller anterolateral femorotibial ligament (ALFTL)
reconstruction using a computerized knee model. American Journal of Sports
Medicine 1985; 14:371-375. (Winner Young Investigator Award)
4. Ridker P, Gibson CM. Atrial
fibrillation induced by breath spray (letter). N Eng J Med 1989; 320:124.
5. Gibson CM, Sandor T, Stone PH, Pasternak RC,
Rosner B, Sacks FM. Quantitative angiographic and statistical methods to assess
serial changes in coronary luminal diameter and implications for
atherosclerosis regression trials. American Journal of Cardiology 1992; 69:1286-1290.
6. Carrozza JP, Kuntz RE, Levine MJ,
Pomerantz RM, Fishman RF, Mansour M, Gibson CM, Senerchia CC, Diver DD,
Safian RD, Baim DS. Angiographic and clinical outcome of intracoronary
stenting: Acute and long-term results from a large single-center experience.
7. Stone PH, Gibson CM, Diaz L,
Pasternak RC, Sandor T, Rosner B, Sacks FM. The natural history of coronary
atherosclerosis using quantitative angiography: Implications for clinical
trials of coronary regression. American Journal of Cardiology 1993; 71:766-772.
8. Gibson CM, Diaz L, Kandarpa K, Sacks FM, Pasternak
RC, Sandor T, Feldman C, Stone PH. The relationship of vessel wall shear stress
to atherosclerosis progression. Arteriosclerosis and Thrombosis 1993;
13:310-315.
9. Kuntz RE, Gibson CM, Nobuyoshi S,
Baim DS. A generalized model of restenosis following conventional angioplasty,
stenting and directional atherectomy.
10. Gibson CM, Kuntz RE, Nobuyoshi M, Rosner B, Baim
DS. Lesion-to-lesion independence of restenosis following treatment by
conventional angioplasty, stenting, or directional atherectomy: Validation for
lesion-based restenosis analysis. Circulation 1993; 87:1123-1129.
11. Gordon PC, Gibson CM, Cohen DJ,
Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within
coronary stents: A quantitative angiographic assessment.
12. Gordon PC, Friederich SP, Piana RN,
Kugelmass AD, Leidig GA, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE,
Baim DS. Is 40-70% diameter narrowing at the site of previous stenting or
directional coronary atherectomy clinically significant? American Journal of
Cardiology 1994; 74:26-32.
13. Ahmed WH, Shubrooks SJ, Gibson CM,
Baim DS, Bittl JA. Complications and long-term outcome after percutaneous
coronary angioplasty in chronic hemodialysis patients. American Heart Journal
1994; 128:252-5.
14. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson
CM, Kugelmass AD, Carrozza JP, Kuntz RE, Baim DS. The incidence and
treatment of "no-reflow" following percutaneous coronary
intervention. Circulation 1994; 89:2514-2518.
15. Antman EM for the TIMI 9A Investigators.
Hirudin in acute myocardial infarction: Safety report from the TIMI 9A trial.
Circulation 1994; 90:1624-1630. (CM Gibson listed in appendix as a
participant of the study group)
16. Cannon CP, McCabe CH, Diver DJ, Herson S,
Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri
S, Davis V, Gibson CM, Poole WK, Braunwald E & THE TIMI 4
INVESTIGATORS. Comparison of front-loaded recombinant tissue-type plasminogen
activator, anistreplase and combination thrombolytic therapy for acute
myocardial infarction: Results of the Thrombolysis in Myocardial Infarction
(TIMI) 4 trial.
17. Sacks FM, Pasternak RC, Gibson CM,
Rosner B, Stone PH. The effect on coronary atherosclerosis of decrease in
plasma cholesterol concentrations in normocholesterolemic patients. Lancet
1994; 344:1182-1186.
18. Kloner RA, Shook TS, Przyklenk K,
19. Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf
B, Flatley M, Alexander B, Diver DJ, McCabe CM, Flaker GC, Baim DS, Braunwald
E. Angiographic predictors of early reocclusion in the TIMI 4 trial.
20. Bittl JA, Strony J, Brinker JA, Ahmed WH,
Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B for the Hirulog
Angioplasty Study Investigators.
Treatment with bivalirudin (Hirulog) as compared with heparin during
coronary angioplasty for unstable angina or postinfarction angina. N Eng J Med
1995;333:764-9. (CM Gibson listed in appendix
as a participant of the study group)
21. Sacks FM, Gibson CM, Rosner B,
Pasternak RC, Stone PH for the Harvard Atherosclerosis Reversibility Project
(HARP) Research Group. The influence of
pre-treatment LDL-cholesterol concentrations on the effect of
hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials.
American Journal of Cardiology 1995; 76:78C-85C.
22. Sacks FM, Pasternak RC, Gibson CM,
Rosner B, Stone PH. The effect on coronary atherosclerosis of fish oil therapy
in patients with normal plasma cholesterol levels.
23. Gibson CM, Cannon CP, Daley WL, Dodge JT,
Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald
E. The TIMI Frame Count: A Quantitative
Method of Assessing Coronary Artery Flow.
Circulation, 1996; 93:879-888.
24. Kloner RA, Gibson CM, Cannon CP,
Braunwald E. Preinfarction angina (letter). N Eng J Med 1996; 335:59-60.
25. Antman EM for the TIMI 9B
Investigators. Hirudin in acute
myocardial infarction. Thrombolysis and thrombin inhibition in myocardial
infarction (TIMI) 9B trial. Circulation 1996; 94:911-921. (CM Gibson
listed in appendix as a participant of the study group)
26. Pasternak RC, Brown LE, Stone PH,
Silverman DI, Gibson CM, Sacks FM.
Combined hypolipidemic drug therapy in normocholesterolemic patients
with coronary heart disease: A stepped-care algorithm with four agents. Annals
of Internal Medicine 1996; 125:529-540.
27. Dotani I, Dodge TJ, Goel M, Al-Mousa EN,
McLean C, Rizzo MJ, Ryan K, Vatner R, Marble SJ, Daley WL, Gibson CM. New Techniques in the angiographic analysis
of coronary flow. Journal of Interventional Cardiology 1996; 9:429-444.
28. Cannon CP, McCabe CH, Gibson CM,
Ghali M, Sequeira RF, McKendall GR, Breed J,
Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E and the TIMI 10A
Investigators. TNK-Tissue
Plasminogen Activator in Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial
Infarction (TIMI) 10A Dose-ranging Trial. Circulation, 1997; 95:351-356.
29. The TIMI 11A Investigators. Dose- ranging trial of Enoxaparin for
unstable angina: Results of TIMI 11A.
30. Gibson CM, Cannon CP, Greene RM, Sequeira RF,
31. Gibson CM, Marble SJ, Rizzo MJ, Moynihan J, McLean
C, Ryan K, Sparano A, Piana RN, McCabe CH, Cannon CP for the TIMI 4 study
group. Relationship between injections
prior to 90 minute angiography and coronary patency. Results of the TIMI 4
trial. American Heart Journal 1997; 134 (3): 351-355.
32. Tanasijevic MJ, Cannon CP, Wybenga DR,
Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Antman EM, Braunwald E
for the TIMI 10A Investigators. Myoglobin, CK-MB and Cardiac troponin-I to
assess reperfusion after thrombolysis for acute myocardial infarction. Results
from TIMI 10A. American Heart Journal
1997; 134: 622-30.
33. The RESTORE Investigators. The effects of
platelet glycoprotein IIb/IIIa blockade with Tirofiban on adverse cardiac
events in patients with unstable angina or acute myocardial infarction
undergoing coronary angioplasty. Circulation 1997; 96:1445-1453. (CM Gibson
listed in appendix as a participant of the study group)
34. Gibson CM, Dodge JT, Goel M, Al-Mousa EN, Rizzo M,
35. Cannon CP. McCabe CH, Borzak S, Henry TD,
Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman
JM, Novotny WF, Braunwald E for the TIMI 12 Investigators. A randomized trial of an oral platelet glycoprotein
IIB/IIIa antagonist, Sibrafiban, in patients post an acute coronary syndrome:
Results of the TIMI 12 trial. Circulation 1998,97:340-349.
(CM Gibson listed in appendix as a participant of the study group)
36. McCormick LS, Black DM, Waters D,
37. Al‑Mousa E, Dodge JT, Rizzo M,
McLean C, Ryan K, Moynihan J, Kelley M, Marble SJ, Goel M, Daley WL, and Gibson
CM: The TIMI frame count in saphenous vein grafts. American Heart Journal
1998;135:323‑328.
38. Dodge JT, Nykiel M, Altman J, Hobkirk K,
Brennan M, Gibson CM. Coronary artery injection technique: A
quantitative in vivo investigation using modern catheters. Cardiac
Catheterization and Diagnosis, 1998, 44:34-39.
39. Dodge JT, Rizzo M, Nykiel M, Altman J,
Hobkirk K, Brennan M, Gibson CM. Impact of injection rate on the TIMI
Frame Count. American Journal of Cardiology, 1998, 81: 1268-1270.
40. Gibson CM, Goel M, Cohen DE, Piana RN, Deckelbaum
LI, Harris KE, King SB for the RESTORE Investigators. Six Month Angiographic
and Clinical Outcomes following IIb/IIIa blockade with Tirofiban. J Am Coll Cardiol 1998; 32:28-34.
41. Gibson CM, Ryan K, Sparano A, Moynihan JL; Rizzo MJ; Kelley M; Marble SJ; Laham R; Simons M; McClusky TR; Dodge JT. Angiographic
Methods to Assess and Classify Human Coronary Angiogenesis. American Heart
Journal, 1999; 137: 169-79.
42. Dauerman HL, Higgins PJ, Baim DS,
Carrozza JP, Kuntz RE, Garber GR, Shubrooks SJ, Sparano AM, Gibson CM,
Cohen DJ. Debulking versus simple balloon angioplasty for the treatment of
diffuse in-stent restenosis. Am J Cardiol 1998; 82:277-284.
43. Dauerman HL, Higgins PJ, Baim DS,
Carrozza JP, Kuntz RE, Garber GR, Shubrooks SJ, Sparano AM, Gibson CM,
Cohen DJ. Debulking versus simple balloon angioplasty for the treatment of
bifurcation lesions. J Am Coll Cardiol, 1998: 1845-1852.
44. Cannon CP, Gibson CM, McCabe CH,
Adgey AAJ, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller
HS, Steingart RM, Fox NL, Weaver WD, Van de Werf F, Braunwald E for the TIMI
10B Investigators. TNK-Tissue Plasminogen Activator compared with Front-loaded
Alteplase in Acute Myocardial Infarction:
Results of the TIMI 10B Trial.
Circulation, 1998; 98:2805-14.
45. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble
SJ, McCabe CH, Cannon CP, Van de Werf F, Braunwald E. The relationship between the TIMI Frame Count
and clinical outcomes after thrombolytic administration. Circulation 1999;
99:1945-1950.
46. Gibson CM, Ryan K, Sparano A, Rizzo M, Moynihan J,
Kelley M, Marble SJ, Dodge JT, Antman EM for the TIMI Study Group. Methodologic
Drift in the Assessment of TIMI Grade 3 Flow and its Implications with Respect
to the Reporting of Angiographic Trial Results. Am
Heart Journal 1999; 137: 1179-1184.
47. Antman EM, Giugliano RP, Gibson CM,
McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht
HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E for the Thrombolysis in
Myocardial Infarction (TIMI) 14 Investigators. Abciximab facilitates the rate
and the extent of thrombolysis: Results of TIMI 14 trial. Circulation 1999;99:2720-2732.
48. Pitt B, Waters D, Brown WV, van Boven AJ,
Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the
Atorvastatin Versus Revascularization Treatment (AVERT) Investigators.
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary
artery disease.
49. Gibson CM, Cannon CP, Murphy SA, Adgey J,
Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Weaver D, Van de Werf F,
Braunwald E. Weight adjusted dosing of TNK-tissue plasminogen activator and its
relationship to angiographic outcomes in the TIMI 10B trial, Am J Cardiol 1999;
84: 976-980.
50. Tanasijevic MJ, Cannon CP, Antman EM,
Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Braunwald E
for the TIMI 10B investigators. Myoglobin, CK-MB and Cardiac troponin – I- 60
minute ratios predict infarct related artery patency after thrombolysis for
acute myocardial infarction. Results from TIMI 10B. J Am Coll Cardiol, 1999;
34:739-47.
51. Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ,
Guigliano RP, Cannon CP, Antman EM, Braunwald E. Impaired coronary blood flow in non-culprit
arteries in the setting of acute myocardial infarction. J Am Coll Cardiol,
1999; 34: 974-82.
52. Gibson CM, Murphy SA, Menown I, Sequeira RF, Greene R, Van de Werf
F, Schweiger MJ, Ghali M; Frey M, Ryan
KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, and Braunwald E for the TIMI
Study Group. Determinants of Coronary Blood Flow Following Thrombolytic
Administration. J Am Coll Cardiol 1999; 34:1403-12.
53. Antman EM, McCabe CH, Gurfinkel EP,
Turpie AGG, Bernink JLM, Salein D, de Luna AB, Fox K, Lablanche JM, Radley D,
Premmereur J, Braunwald E for the TIMI 11B Investigators. Circulation 1999;
100:1593-1601. (CM Gibson listed in appendix as a participant of the
study group)
54. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley
R, Marble SJ, McCabe CH, Van de Werf F
and Braunwald E for the TIMI Study Group. Relationship of TIMI myocardial
perfusion grade to mortality after administration of thrombolytic drugs.
Circulation, 2000; 101:125-130.
55. de Lemos JA, Antman EM, Gibson CM,
McCabe CH, Giugliano RP, Murphy SA, Frey MJ,
Van der Wieken R, Van de Werf F, and Braunwald E the TIMI 14 Investigators. Abciximab Improves
Both Epicardial Flow and Myocardial Reperfusion in ST Elevation Myocardial
Infarction: A TIMI 14 Analysis. Circulation, 2000; 101: 239-243.
56. de Lemos JA, Antman EM, Giugliano RP,
McCabe CH, Murphy SA, Van de Werf F, Gibson
CM, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14
Investigators. Resolution of ST-Segment Elevation Correlates with Infarct
Related Artery Patency and Flow After Thrombolytic
Therapy. Am J Cardiol 2000; 85:299-304.
57. Dauerman HL, Pinto DS, Ho KKL, Gibson
CM, Kuntz RE, Cohen DJ, Baim DS, Carrozza JP. Outcome of patients with
acute myocardial infarction who are ineligible for primary angioplasty. Cathet
Cardiovasc Intervent 2000; 49: 237-243.
58. Cannon L, Senior D, Fiet F, Attubato M,
Rosenberg J, O’Donnell M, Hirst J, Gibson M. Results from the
intermediate vessel atherectomy trial (IVAT). Catheterization and
Cardiovascular Interventions 2000; 49:396-400.
59. Coulter SA, Cannon CP, Ault KA, Antman
EM, Van de Werf F, Adgey AAJ, Gibson CM, Giugliano RP, Mascelli MA,
Scherer J, Barnathan ES, Braunwald E, Kleiman NS. High Levels of Platelet
Inhibition With Abciximab Despite Heightened Platelet Activation and
Aggregation During Thrombolysis for Acute Myocardial Infarction
: Results From TIMI (Thrombolysis In Myocardial Infarction) 14.
Circulation 2000;101 2690-2695
60. Llevadot J, Giugliano RP, McCabe C,
Cannon CP, Antman EM, Murphy S, Gibson CM for the TIMI
Investigators. Mild obstruction in the
culprit artery after thrombolytic administration: Characterization and insight
on the degree of residual stenosis. Am J Cardiol 2000; 85:1409-1413.
61. Cannon CP, Gibson CM, Lambrew CT,
Tiefenbrunn AJ, French WJ, Gore JM, Hilbe J, Sanathanan L, Weaver WD, Rogers WJ
for the NRMI-2 Investigators.
Relationship of Door-to-Balloon Time to Mortality in Patients with Acute
Myocardial Infarction Treated with Primary Angioplasty. JAMA 2000; 283:2941-7.
62. de Lemos JA, Antman EM, Morrow DA,
Llevadot J, Giugliano RP, Coulter SA, Schuhwerk K, Arslanian S, McCabe CH, Gibson
CM, Rifai N. Heart-type Fatty Acid Binding Protein as a marker of
reperfusion after thrombolytic therapy. Clin Chimica Acta 2000; 298:85-97.
63. Fang JC, Kinlay S, Wexberg P, Amirzadeh
A, Gibson CM, Ganz P. Use of the TIMI Frame Count for the quantitative
assessment of transplant associated arteriosclerosis. Am J Cardiol. 2000 Aug 15;86(8):890-892.
64. Dotani MI,
Elnicki DM, Jain AC, Gibson CM. Association
between pre-operative statin therapy and cardiac outcomes after coronary artery
bypass grafting. Am J Cardiol 2000 Nov 15;86(10):1128-1130.
65. Barron HV, Cannon CP, Murphy SA,
Braunwald E, Gibson CM. The association between white blood cell count,
epicardial blood flow, myocardial perfusion and clinical outcomes in the
setting of acute MI. A TIMI 10B substudy. Circulation. 2000 Nov 7;102(19):2329-34.
66. Antman EM, Gibson CM, de Lemos JA,
Giugliano RP, McCabe CH, Coussement P, Menown I, Nienaber CA, Frey MJ, Van der
Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E for the
TIMI Investigators. Combination
reperfusion therapy with abciximab and reduced dose Reteplase: Results from
TIMI 14. Eur Heart J. 2000 Dec 1;21(23):1944-1953.
67. Roe MT, Giugliano RP, Harrington RA, Gibson
CM, Strony J, Kitt MM, Califf
RM, Braunwald E. Combination reperfusion therapy for acute
myocardial infarction with eptifibatide and tenecteplase. Design and methodology of the (INTEGRILIN and
tenecteplase in acute myocardial infarction) INTEGRITI trial. Heart Drug 2000;1:5-13.
68. Gibson CM, Anshelevich M, Murphy S, Luu L, Hynes
C, Kliris J, Kermgard S, Otten MHC, Antman EM, Cannon CP, Braunwald E for the
TIMI study group. Impact of injections during diagnostic coronary angiography
on coronary patency in the setting of acute myocardial infarction from the TIMI
trials. Am J Cardiol. 2000 Dec 15;86(12):1378-1379.
69. Gibson CM, Goel, M, Rizzo M, Ryan K, Marble SJ,
Deckelbaum L, King S for the RESTORE Investigators. Impaired Coronary Blood
Flow in Non-Culprit Arteries in the Setting of Acute Coronary Syndromes: A
RESTORE substudy. Am J Cardiol. 2000 Dec 15;86(12):1375-1377.
70. Gibson CM, Murphy SA, Marble SJ, McCabe CH, Antman
EM, Cannon CP, Braunwald E for the TIMI Study Group. Can we replace the 90
minute TIMI flow grades with those at 60 minutes as an endpoint in thrombolysis
trials? Am J Cardiol. 2000 Dec 15;86(12):1375-1377.
71. Wang-Clow F, Fox NL, Cannon CP, Gibson
CM, Berioli S, Bluhmki E, Danays T, Braunwald E, Van De Werf F, Stump DC.
Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am
Heart J 2001 Jan;141(1):33-40.
72. Direct Thrombin Inhibitor Trialists’
Collaboration. Direct thrombin
inhibitors in acute coronary syndromes and during percutaneous coronary
intervention. Design of a meta-analysis based on individual patient data. CM
Gibson is a member of the Direct Thrombin Inhibitor Trialists’
Collaboration and is listed with all authors in the appendix. Am Heart Journal website, 2001, in press.
73. de Lemos, JA, Gibson CM, Antman
EM, Murphy SA, Schuhwerk KM, Schweiger M, Coussement P, Van de Werf F, Braunwald
E for the TIMI 14 Investigators. Abciximab and early adjunctive percutaneous
coronary intervention enhance microvascular perfusion after thrombolysis:
Observations from the TIMI 14 Trial. Am Heart Journal
2001; 141:592-598.
74. Gibson CM, Kirtane AJ, Murphy SA, Marble SJ, de
Lemos JA, Antman EM, Braunwald E for the TIMI Study Group. Impact of Contrast
Agent Type (Ionic versus Non-ionic) Used for Coronary Angiography on
Angiographic, Electrocardiographic and Clinical Outcomes Following Thrombolytic
Administration in Acute MI. Catheter Cardiovasc Interv. 2001 May;53(1):6-11.
75. Cannon CP, Weintraub WS, Demopoulos LA,
Vicari R, Frey MJ, Lakkis N, Neumann FJ, Gibson CM, Robertson DH,
DeLucca PT, McCabe CH, Braunwald E for the Treat Angina with Aggrastat and Determine
Cost of Therapy with an Invasive or Conservative Strategy (TACTICS)-TIMI 18
Investigators. Comparison of early invasive versus early conservative
strategies in patients with unstable angina and non-ST elevation myocardial
infarction treated with early glycoprotein IIb/IIIa inhibition. N Engl J Med.
2001 Jun 21;344(25):1879-87.
76. Gibson CM, de Lemos JA, Murphy SA, Marble SJ,
McCabe CH, Cannon CP, Antman EM, Braunwald E for the TIMI Study Group.
Combination Therapy with Abciximab Reduces Angiographically Evident Thrombus in
Acute MI: A TIMI 14 Substudy. Circulation. 2001 May 29;103(21):2550-4.
77. Srinivas VS,
Cannon CP, Gibson CM, Antman EM,
Tanasijevic MJ, Murphy S, Sokol S, Braunwald E, Mueller HS. Use
of myoglobin levels at 12 hours to identify patients at low risk for 30-day
mortality following thrombolysis for acute myocardial infarction: a TIMI 10B
substudy. Am Heart J. 2001 Jul;142(1):29-36.
78. Gibson CM, Cohen D, Cohen E, Liu H, Murphy S,
Marble SJ, Lorenz T, Kitt M, Tcheng JE for the ESPRIT study Group. Treatment
with Eptifibatide and Coronary Flow Reserve (CFR)
Following Elective Stent Placement: An ESPRIT Substudy. Am J Cardiol 2001,
Jun 1;87(11):1293-5.
79. Peters RJG, Spickler W, Theroux P, White
H, Gibson CM, Molhoek PG, Anderson HV, Hirsh J, Weaver D. Randomized
comparison of vasoflux, a novel anticoagulant, and heparin as adjunctive
therapy to streptokinase for acute myocardial infarction. Results of the VITAL
study: Vasoflux International Trial for AMI Lysis. Am Heart J 2001; 142:237-43.
80. de Lemos JA, Morrow DA, Gibson CM,
Murphy SA, Rifai N, Tanasijevic M, Giugliano RP, Schuhwerk KC, McCabe CH,
Cannon CP, Antman EM, Braunwald E for the TIMI 14 Investigators. Early
Noninvasive Detection of Failed Epicardial Reperfusion After
Fibrinolytic Therapy. Am J Cardiol 2001, Aug 15;88(4):353-8.
81. Schweiger MJ, Cannon CP, Murphy SA, Gibson CM, Cook JR, Giugliano RP, Changezi HU, Antman EM,
Braunwald E for the TIMI 10B and TIMI 14 Investigators. Early Coronary
Intervention Following Pharmacologic Therapy for Acute Myocardial Infarction-
The Combined TIMI 10B- TIMI 14 Experience. Am J
Cardiol 2001, 88(8): 831-836.
82. Solomon DH,
Stone PH, Glynn RJ, Ganz DA, Gibson CM, Tracy R,
Avorn J. Use of Risk Stratification To Identify Patients With Unstable Angina
Likeliest to Benefit From an Invasive Versus Conservative Management Strategy.
J Am Coll Cardiol. 2001 Oct;38(4):969-76.
83. Angeja BG, Alexander JH, Chin R, Li X,
Barron HV, Granger CB, Van de Werf F, Gibson CM. Safety of the
Weight-Adjusted Dosing Regimen of Tenecteplase in the ASSENT-2 Trial. Am J Cardiol 2001; 88:1240-1245.
84. Baran KW, Nguyen M, McKendall GR,
85. Gibson CM, Murphy SA, Hynes C, Marble SJ, Cohen
DJ, Cohen E, Lui
HK, Kitt MM, Lorenz TJ, and Tcheng
JE for the ESPRIT study group.
Relationship of CK-MB Release to TIMI Myocardial Perfusion Grade Following
Intracoronary Stent Placement: An ESPRIT Substudy. Am Heart J. 2002 Jan;143(1):106-110.
86. Angeja BG, Gunda M, Murphy SA, Sobel BE, Rundle
AC, Syed M, Asfour A, Borzak S, Gourlay
SG, Barron HV, Gibbons RJ, Gibson CM for
the LIMIT AMI Study Group. TIMI Myocardial Perfusion Grade and ST Segment
Resolution: Association with Infarct Size as Assessed by Single Photon Emission
Computed Tomography Imaging. Circulation. 2002 Jan 22;105(3):282-5.
87. Becker RC, Spencer FA, Gibson M,
Rush J, Sanderink G, Murphy S, Ball SP, Antman E for the TIMI 11A
investigators. Influence of patient characteristics and renal function on
factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin
administration in non-ST-segment elevation acute coronary syndromes. Am Heart
J. 2002 May;143(5):753-9.
88. Solomon DH, Ganz DA, Avorn J, Glynn RJ,
Knight EL, Gibson CM, Stone PH. Which patients with unstable angina or
non-Q-wave myocardial infarction should have immediate cardiac catheterization?
A clinical decision rule for predicting who will fail medical therapy. Journal of Clinical
Epidemiology 55 (2002) 121–128.
89. Colyer WR Jr,
Burket MW, Ansel GM, Ramee SR, Minor RL, Gibson
CM, Cooper CJ. Intra-aortic balloon pump placement following aorto-iliac
angioplasty and stent placement. Catheter Cardiovasc Interv 2002 Feb;55(2):163-168.
90. Cannon CP, Bahit MC, Haugland JM, Henry TD, Schweiger MJ,
McKendall GR, Shah PK, Murphy SA, Gibson
CM, McCabe CH, Antman EM, Braunwald E for the TIMI 9 Registry
Investigators. Underutilization of evidence-based medications in Acute ST
Elevation Myocardial Infarction: Results
of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Critical
Pathways in Cardiology, 2002; 1: 44-52.
91. Antman EM, Louwerenburg HW, Baars HF,
Wesdorp JCL, Hamer B, Bassand JP, Bigonzi F, Pisapia G, Gibson CM, Heidbuchel H, Braunwald E, and Frans Van de Werf F for
the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Investigators.
Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial
Infarction: Results of the ENTIRE-TIMI 23 Trial. Circulation. 2002 Apr 9;105(14):1642-9.
92. Gibson CM,
Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E for the TIMI Study
Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame
count, and percutaneous coronary intervention to long-term outcomes after
thrombolytic administration in acute myocardial infarction. Circulation, 2002;
105:1909-1913.
93. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, McCabe CH, Antman
EM, Cannon CP, Braunwald E. A
multimarker approach to risk stratification in non-ST elevation acute coronary
syndromes: Simultaneous assessment of troponin I, c-reactive
protein and B-type natriuretic peptide.
Circulation. 2002 Apr 16;105(15):1760-3.
94. Angeja BG, Gibson CM, Chin R,
Frederick PD, Every NR, Ross AM, Stone GW, and Barron HV for the Participants
in the National Registry of Myocardial Infarction 2-3. Predictors of
door-to-balloon delay in primary angioplasty. Am J Cardiol. 2002 May 15;89(10):1156-61.
95. Gibson CM, Chen M, Goel
M, Angeja BG, Murphy SA, Marble SJ, Cannon CP, for the TIMI Study Group.
Precordial ST-Segment Depression in Inferior Myocardial Infarction is
Associated with Slow Flow in the Non-Culprit Left Anterior Descending Artery. J
Thromb Thrombolysis 2002 Feb;13(1):9-12.
96.
Gibson CM, Dotani MI, Murphy SA, Marble SJ, Dauterman KW, Michaels AD, Dodge JT
for The RESTORE Investigators. Correlates of Coronary
Blood Flow Before and After Percutaneous Coronary
Intervention and Their Relationship to Angiographic and Clinical Outcomes in
the RESTORE Trial. Am Heart J. 2002 Jul;144(1):130-5.
97.
Antman EM, Cooper H, Gibson
CM, de Lemos JA, McCabe CH, Giugliano RP, Coussement P, Murphy SA, Scherer
J, Anderson K, Van de Werf F, Braunwald E for the Thrombolysis in Myocardial
Infarction (TIMI) 14 Investigators. Determinants
of Improvement in Epicardial Flow and Myocardial Perfusion for ST Elevation Myocardial
Infarction: Insights from TIMI 14 and InTIME-II. European Heart Journal (2002) 23, 928–933.
98. Bahit MC,
Murphy SA, Gibson CM, Cannon
CP. Critical pathway for acute ST-segment elevation myocardial
infarction estimating its potential impact in the TIMI 9 trial registry.
Critical Pathways in Cardiology, 2002 (1); 107-112.
99. Gibson
CM, Frisch D, Murphy SA,
Gourlay SG, Gibbons R, Barron HV for the LIMIT AMI Study Group. The
Relationship of Intracoronary Stent Placement Following Thrombolytic Therapy to
Tissue Level Perfusion. Journal of Thrombolysis and Thrombosis, 2002 Apr;13(2):63-8.
100.
Michaels
AM, Appleby M, Dauterman K, Ports TA, Chou TM, Gibson CM. Pretreatment with Intragraft Verapamil Prior to
Percutaneous Coronary Intervention of Saphenous Vein Graft Lesions: Results of
the Randomized, Controlled Vasodilator Prevention of
No-Reflow (VAPOR) Trial. J Invasive Cardiol. 2002 Jun;14(6):299-302.
102.
Wong
GC, Kraimer N, Pai R, James D, Murphy SA, Cannon CP, Gibson CM for the TACTICS-TIMI 18 Study Group. Elevations in
Troponin T are Associated with Abnormal Tissue Level
Perfusion: A TACTICS-TIMI 18 Substudy. Circulation. 2002;106:202-207.
103.
de
Lemos JA, Morrow DA, Gibson CM,
Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E.
The prognostic value of serum myoglobin in patients with non-ST segment
elevation acute coronary syndromes:
results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol
2002;40:238–44.
104.
Scirica
BM, Cannon CP, Antman EM, Murphy SA,
Morrow D, Sabatine MS, McCabe CH, Gibson
CM, Braunwald E. Validation of the Thrombolysis in Myocardial Infarction
(TIMI) Risk Score for unstable angina and non-ST-elevation myocardial
infarction in the TIMI III Registry. Am J Cardiol 2002 Aug 1;90(3):303-5.
105.
Scirica
BM, Cannon CP, Gibson CM, Murphy SA,
Moliterno DJ, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp
SK, Booth JE, Ferguson JJ, Braunwald E. The effect of clinical guidelines on
the management of unstable angina and non-ST-elevation myocardial infarction in
the TIMI III (1990-93) and the GUARANTEE (1995-96) Registries. Critical Pathways in Cardiology, 2002: 150–158.
106.
Brener
SJ, Murphy SA, Gibson CM, DiBattiste
P, Demopolous L, and
Cannon CP for the TACTICS Investigators. Efficacy and Safety of Multivessel
Coronary Intervention in Patients with Acute Coronary Syndromes. Am J Cardiol 2003, 90: 631-693.
107.
Sabatine
MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH,
Braunwald E, Gibson CM. Elevated white blood cell count is associated
with higher mortality in patients with acute coronary syndromes (ACS) independent of
other cardiac markers: A TACTICS TIMI 18 substudy. J Am Coll Cardiol. 2002 Nov
20;40(10):1761-8.
108.
Angeja
B, de Lemos JA, Murphy SA, Marble SJ, Antman EM, Cannon CP, Braunwald E, Gibson
CM. Infarct artery patency and microvascular perfusion among diabetics with
acute myocardial infarction receiving thrombolysis. Am Heart J. 2002 Oct; 144(4):649-56.
109. Murphy SA, Chen C, Cannon CP, Braunwald E, Gibson CM. The impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute MI. Am J Cardiol 2002 Oct 1;90(7):766-770.
110.
Popma
JJ, Hauptmann KE, Reifart N, Virmani R, Cox N, Esfir K, McColl M, Tully G,
Murphy SA, Gibson CM, Grube E.
Initial Clinical Experience with Distal Coronary Protection using the
FilterWire Exä in Patients Undergoing Coronary Artery
and Saphenous Vein Graft Percutaneous Intervention. Catheter Cardiovasc Interv.
2002 Oct; 57(2):125-134.
111.
Cooper
HA, de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Gibson CM, Antman EM, Braunwald E.
Minimal ST-Segment Deviation: A Simple, Noninvasive Method to Identify Patients
with a Patent Infarct-Related Artery following Fibrinolysis. Am Heart J. 2002
Nov; 144(5):790-5.
112.
Angeja
BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, Cannon CP, Braunwald E,
and Gibson CM for the TIMI Study
Group. The Smoker’s Paradox: Insights
from the Angiographic Substudies of the TIMI Trials. J Thromb Thrombolysis.
2002 Jun;13(3):133-9.
113.
Sharis
PJ, Cannon CP, Rogers WJ, McCabe C, Murphy S, Gibson CM, Stone PH,
Braunwald E. Predictors of mortality, coronary angiography and
revascularization in unstable angina and acute non-q wave myocardial infarction
(The TIMI III Registry). Am J Cardiol. 2002 Nov 15;90(10):1154-1156.
114.
Bahit MC, Cannon CP, Antman EM, Murphy SA, Gibson
CM, McCabe CH, Braunwald E. Direct comparison of characteristics,
treatment, and outcomes of patients enrolled versus patients not enrolled in a
clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry.
Am Heart J. 2003 Jan;145(1):109-17.
115.
de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon
CP, and Braunwald E for the TIMI Study Group. Plasma Levels of Monocyte
Chemoattractant Protein-1 in Patients with Acute Coronary Syndromes. Circulation 2003;107 690-695.
116.
Henry
TD, Annex BH, McKendall GR, Azrin, MA, Lopez JJ, Giordano FJ, Shah PK,
Willerson JT, Benza RL, Berman DS, Gibson
CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER for the VIVA Investigators.
The VIVA Trial: Vascular Endothelial
Growth Factor in Ischemia for Vascular Angiogenesis. Circulation.
2003 Mar 18;107(10):1359-65.
117.
Murphy
SA, Chen C, Gourlay S, Barron HV, Gibson
CM. Impaired tissue level perfusion in the non-culprit artery territory in
the setting of acute MI. Am J
Cardiol. 2003 Feb 1;91(3):325-8.
118.
Pinto D, Murphy SA, Marble SJ, Cannon CP,
Braunwald E, Gibson CM. An Activated
Clotting Time (ACT) of < 250 is Associated with
Higher Adverse Event Rates: A TACTICS TIMI 18 Substudy. Am J Cardiol 2003 Apr 15;91(8):976-978.
119.
Morrow
DA, de Lemos JA, Sabatine MS, Murphy SA, Demopolous LA, DiBattiste PM, McCabe
CH, Gibson CM, Cannon CP, and
Braunwald E. Evaluation of B-type Natriuretic Peptide for Risk Assessment in
UA/NSTEMI: BNP and Prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264 –72.
120.
Giugliano RP, Roe MT, Harrington RA, Gibson CM, Zeymer U, Van de Werf F,
Baran K, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH,
Braunwald E, Califf RM, MD on behalf of the INTEGRITI Investigators.
Combination Reperfusion Therapy With Eptifibatide and Reduced Dose Tenecteplase
For ST-Elevation Myocardial Infarction: Results of the Integrilin® and
Tenecteplase in Acute Myocardial Infarction (INTEGRITI) Phase II Angiographic
Trial. J Am Coll Cardiol 2003;41:1251– 60ii.
121.
Dotani MI, Morise AP, Haque R, Jain AC, Gibson CM. Association Between Short Term Lipid Lowering Before CABG and
Post-Operative Myocardial Blood Flow as Assessed by Positron Emission
Tomography. Am J Cardiol. 2003 May 1;91(9):1107-9.
122.
Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Overview of
Corticosteroid treatment for acute myocardial infarction. Am J Cardiol. 2003
May 1;91(9):1055-9.
123.
Weber JE, Gibson CM, Murphy SA, Larkin
GL, Hollander JE. Cocaine induced myocardial infarction is associated with
reduced microvascular perfusion. Acad Emerg Med 2003 May;10(5):428-9.
124.
Wong GC, Frisch D, Murphy SA, Sabatine MS, Pai
R, James D, Kraimer N, Katsiyiannis PT, Marble SJ, DiBattiste PT, Demopoulos LA, Gourlay SG, Barron HV, Cannon CP, Gibson CM, for the LIMIT AMI and TACTICS-TIMI 18 Study Groups. Time
for Dye to Traverse the Epicardial Artery and the Myocardium in Acute ST
Segment Elevation Myocardial Infarction Versus Unstable Angina / Non ST
Elevation MI. Am J Cardiol 2003 May
15;91(10):1163-7.
125.
Gibson CM, Karha J, Murphy SA James DJ, Antman EM, Cannon CP, Braunwald E for the
TIMI Study Group. Early and Long Term Clinical Outcomes Associated with
Reinfarction Following Fibrinolytic Administration. J Am Coll Cardiol 2003;42:7–16.
126. Murphy SA, Dauterman K, de Lemos JA, Kermgard S, Marble SJ, Antman EM, Braunwald E, and Gibson
CM for the
Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Non-Q-Wave MI in
the Modern Thrombolytic Era: Angiographic and Clinical Characteristics
Associated with the Development of Non-Q-Wave MI in the TIMI 14 trial. Am Heart
J. 2003 Jul;146(1):42-7.
127. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy
SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönbeck U. Soluble
CD40L Risk Prediction After Acute Coronary Syndromes. Circulation. 2003;108:r43-r46.
128. Weber J,
Murphy SA, Braunwald E, Gibson CM. Epicardial and myocardial perfusion
abnormalities in the setting of cocaine induced myocardial infarction. J Thromb
Thrombolysis. 2002;14(3):239-45.
129. Chen EW, Canto
JG, Parson LS, Peterson ED, Littrell K, Every NR, Gibson CM, Hochman JS, Ohman EM, Cheeks M, Barron HV for the Investigators in the National Registry of
Myocardial Infarction. Relation Between Hospital
Intra-aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial
Infarction Complicated by Cardiogenic Shock.
Circulation. 2003 Aug 11 [Epub ahead of print] .
130.
Gibson CM, de Lemos JA, Murphy SA, Marble SJ,
Antman EM, Cannon CP. Methodologic and Clinical Validation of the TIMI
Myocardial Perfusion Grade in Acute MI. J Thromb Thrombolysis. 2002;14(3):233-7.
131.
Gibson CM,
Gibson WJ, Murphy SA, Marble SJ, McCabe CH, Turakhia MP, Kirtane AJ, Karha J, Aroesty JM, Giugliano RP, Antman EM. The association of the Fibonacci cascade
with the distribution of coronary artery lesions responsible for ST segment
elevation myocardial infarction. Submitted to Am J Cardiol, 2003;92(5):595-7.
132.
Karha
J, Murphy SA, Kirtane AJ, de Lemos JA, Aroesty JM, Cannon CP, Antman EM,
Braunwald E, and Gibson CM for the
TIMI Study Group. Association of Proximal Culprit Artery Lesion Location with
Clinical Outcomes In Acute Myocardial Infarction. Am J Cardiol. 2003;92(8):913-8.
133. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003;42(9):1535-43.
134.
Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon
CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance From
the Coronary Ostium to the Culprit Lesion in Acute ST-Elevation Myocardial
Infarction and its Implications Regarding The Potential Prevention of Proximal
Plaque Rupture. J Thromb Thrombolysis. 2003; 15(3): 189-96.
135.
Roe
MT, Green CL, Giugliano RP, Gibson CM,
Baran K, Greenberg M, Palmeri ST, Crater S, Trollinger K, Hannan K, Harrington
RA, Krucoff MW; INTEGRITI Investigators. Improved speed and stability of
st-segment recovery with reduced-dose tenecteplase and eptifibatide compared
with full-dose tenecteplase for acute st-segment elevation myocardial
infarction. J Am Coll Cardiol. 2004;43(4):549-56.
136.
Wiviott SD, Cannon CP,
Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano
RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential
expression of cardiac biomarkers by gender in patients with unstable
angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina
with Aggrastat and determine Cost of Therapy with an Invasive or Conservative
Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004;109(5):580-6.
137.
Kirtane A, Barron HV,
MurphySA, Gibson CM. Association of absolute neutrophil count with
patency in AMI. Am
J Cardiol. 2004;93(5):532-6.
138.
Gibson CM, Karha J,
Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon
CP, Antman EM, Califf RM, Braunwald E for the TIMI Study Group. Association of a Pulsatile Blood Flow
Pattern on Coronary Arteriography and Short-Term Clinical Outcomes in Acute
Myocardial Infarction. J Am Coll Cardiol. 2004;43(7):1170-6.
139.
Choi JW, Gibson
CM, Murphy SA, Davidson CJ, Kim RJ, Ricciardi M. Myonecrosis following
stent placement: Association between impaired TIMI myocardial perfusion grade
(TMPG) and MRI visualization of microinfarction. Catheter Cardiovasc Interv.
2004;61(4):472-6.
140.
Hobbach
HP, Gibson CM, Giugliano RP, Hundertmark J, Schaeffer C, Tscherleniak W,
Schuster P. The prognostic value of serum creatinine on admission in
fibrinolytic-eligible patients with acute myocardial infarction. J
Thromb Thrombolysis. 2003;16(3):167-74.
141.
McCullough PA, Gibson CM, DiBattiste PM, Demopoulos LA, Murphy SA, Weintraub WS,
Neumann FJ, Khanal S, Cannon CP for the TACTICS TIMI-18 Investigators. Timing
of angiography and revascularization in acute coronary syndromes: an analysis from the TACTICS-TIMI 18 trial. J
Interv Cardiol. 2004;17(2):81-86.
142.
Gibson CM, Karha J, Giugliano RP, Roe MT,
Murphy SA, Harrington RA, Green CL, Schweiger MJ, Miklin JS, Baran KW,
Palmeri S, Braunwald E, and Krucoff MW for the INTEGRITI Study Group. Impaired TIMI
epicardial flow and myocardial perfusion grades are associated with increased
time to ST segment recovery in ST segment elevation MI: An INTEGRITI
substudy. Am Heart J. 2004;147(5):847-52.
143.
Giugliano RP, Sabatine MS,
Gibson CM, Roe MT, Harrington RA,
Murphy SA, DA Morrow, EM Antman, and E Braunwald. Combined assessment of
thrombolysis in myocardial infarction flow grade, myocardial perfusion grade,
and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am
J Cardiol 2004 93(11): p. 1362.
144.
Herrmann
HC, Murphy SA, DiBattiste PM, DeLucca, PT, Demopoulos LA, Gibson CM and
Cannon CP. Greater Benefit of Early Invasive Strategy for Unstable Angina and
Non-ST Elevation Myocardial Infarction in United States Compared with
Non-United States Patients: A
TACTICS-TIMI 18 Substudy. Critical Pathways in Cardiology, 2004;3(2): 95-100.
145.
Gibson CM, Bigelow B,
James D, Tepper MR, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E
for the TIMI Study Group. Association of American College of Cardiology/American
Heart Association Task Force Classification of Lesion Complexity Following
Fibrinolytic Administration with
Mortality in ST Elevation Myocardial Infarction. Am
J Cardiol. 2004;94(1):108-11.
146.
Morrow DA, Antman EM,
Murphy SA, Assmann SF, Giugliano RP, Cannon CP, Gibson CM, McCabe CH, Barron HV, Van De Werf F, and Braunwald E. The
Risk Score Profile: a novel approach to characterising the risk of populations
enrolled in clinical studies. Eur Heart J 2004 25(13): 1139.
147.
Gibson CM and Schomig A. Coronary and
myocardial angiography: angiographic assessment of both epicardial and
myocardial perfusion. Circulation 2004 109(25): p. 3096-3105.
148.
Gardner
GS, Frisch
DR, Murphy SA, Aroesty JM, Giugliano RP, Antman EM, Braunwald E and Gibson
CM for the TIMI Study Group. Improvements in Epicardial Flow in Nonculprit
Arteries Following Rescue or Adjunctive PCI of the Culprit Artery After Fibrinolytic Administration. Am J Cardiol 2004, Am J Cardiol 2004;94:178–180.
149.
Mega
JL, Morrow DA, deLemos JA, Sabatine MS, Murphy SA, Rifai N, Gibson CM, Antman EM, Braunwald E. BNP
at Presentation and Prognosis in Patients with ST-Elevation Myocardial
Infarction: An ENTIRE-TIMI 23 Substudy. J Am Coll Cardiol. 2004 Jul 21;44(2):335-9.
150.
Gibson
CM, Jennings LK, Lorenz D, Giugliano RP, Harrington RA, Roe MT, Murphy SA,
Cholera S, Baran KW, Hobbach H, Braunwald E.
Increased platelet receptor occupancy following eptifibatide therapy is
associated with improved patency, tissue level perfusion and ST segment
resolution in ST segment elevation myocardial infarction: An
INTEGRITI substudy. Circulation 2004;110(6):679-84.
151.
Gibson
CM, Murphy SA, Morrow
DA, Aroesty JM, Gibbons RJ, Gourlay SG, Barron HV, Giugliano RP, Antman EM,
Braunwald E. Angiographic Perfusion Score: An Angiographic Variable That
Integrates Both Epicardial and Tissue Level Perfusion Before and After Facilitated
Percutaneous Coronary Intervention in Acute Myocardial Infarction. Am Heart J. 2004 Aug;148(2):336-40.
152.
Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, Gibson CM, McCabe CH, Cannon CP, Antman EM, Braunwald E. Performance of the Thrombolysis In Myocardial Infarction Risk Index in
the National Registry of Myocardial Infarction-3 and -4. A Simple Index That
Predicts Mortality in ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol 2004;44:783–9.
153.
Sadanandan S, Cannon
CP, Gibson CM, Desai R, Murphy SA, DiBattiste PM, Braunwald E. A risk score for predicting coronary artery
bypass surgery in patients with non-ST elevation acute coronary syndromes. J Am Coll Cardiol 2004;44:799–803.
154.
Sadanandan S, Cannon CP, Cheuri K, Murphy SA,
DiBattiste PM, Morrow DA, de Lemos JA, Braunwald E, Gibson CM. Association of elevated B-type natriuretic peptide
levels with angiographic findings among patients with unstable angina and non
ST elevation myocardial infarction. J Am Coll Cardiol 2004;44:564–8.
155.
Gibson CM, Singh KP, Murphy SA, DiBattiste P,
Demopoulos L, Cannon CP and Braunwald E for the TIMI Study Group. Association Between Duration of Tirofiban Therapy Before Percutaneous
Intervention and Tissue Level Perfusion: A TACTICS-TIMI 18 Substudy. Am J
Cardiol 2004, Am J Cardiol. 2004
Aug 15;94(4):492-4.
156.
Goldstein JA, Massey KD,
Kirby S, Gibson CM, Hettiarachchi J,
Rankin AJ & Jackson NC. Effect of high-dose intravenous eletriptan on
coronary artery diameter. Effect
of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia.
2004 Jul;24(7):515-521.
157.
Gibson
CM, Murphy SA, Kirtane
AJ, Giugliano RP, Cannon CP, Antman EM, and Braunwald E for the TIMI Study
Group. Association of Duration of Symptoms at Presentation with Angiographic
and Clinical
Outcomes Following Fibrinolytic Therapy. J Am Coll Cardiol. 2004 Sep 1;44(5):980-7.
158.
Kirtane
AJ, Bui A, Murphy SA, Karmpaliotis D, Rahman A, Aroesty JM, Giugliano RP, Cannon
CP, Antman EM, and Gibson CM for the TIMI Study Group. Association of Epicardial and
Tissue-level Reperfusion with Left Ventricular End-Diastolic Pressures in
ST-Elevation Myocardial Infarction. Journal of Thrombosis and
Thrombolysis 17(3), 177–184, 2004.
159.
Kashani A, Giugliano RP, Antman EM, Morrow DA, Gibson CM, Murphy SA, and Braunwald E.
Severity of Heart Failure, Treatments, and Outcomes After Fibrinolysis in
Patients With ST-Elevation Myocardial Infarction. Eur Heart J 1 Oct 2004 25(19): p. 1702.
160.
Bhatt
DL, Roe MT, Peterson E, Li Y, Harrington RA Greenbaum AB, Berger PB, Cannon CP,
Cohen DA, Gibson CM, Saucedo J, Kleiman NS, Hochman JS, Boden W, Brindis RG, Peacock WF, Smith SC, Pollack
CV, Gibler WB, and Ohman EM for the CRUSADE Steering Committee. An Early
Invasive Strategy is Underused in the
Treatment of Acute Coronary Syndromes - Results from the CRUSADE Registry. JAMA. 2004;292:2096-2104.
161.
Karmpaliotis
D, Turakhia MP, Morrow DA, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson
CM. Sequential Risk Stratification using the TIMI Risk Score and TIMI Flow
Grade among Patients Treated with Fibrinolytic Therapy for acute ST Segment
Elevation Myocardial Infarction. Am J Cardiol 1 Nov 2004
94(9): p. 1113.
162.
Gibson CM. NRMI and current treatment patterns
for ST-elevation myocardial infarction. Am Heart J 1 Nov 2004 148(5 Suppl): p.
S29.
163.
In press
164.
Gibson
CM, Dumaine R, Murphy
SA, Cannon CP, Antman EM, Braunwald E. Association of Glomerular Filtration
Rate on Presentation in Unstable Angina and Non ST Elevation Myocardial
Infarction with Subsequent Mortality. Eur H Journal, 2004 in press.
165.
Turakhia M, Pinto T, Murphy SA, Antman EM, Cannon
CP, Braunwald E, Gibson CM.
Higher platelet counts are associated with greater thrombus burden in
patent arteries following thrombolytic administration: A TIMI angiographic substudy. Am J Cardiol, 2004 in press.
166. Mega JL, Morrow DA, Sabatine MS, Zhao XQ, Snapinn SM, DiBattiste PM, Gibson CM, Antman EM, Braunwald E, Theroux P. Correlation between the TIMI Risk Score and High Risk Angiographic Findings in Non-ST Elevation Acute Coronary Syndromes: Observations from PRISM-PLUS. Am Heart J 2004; (In press)
167. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Roe MT, Harrington RA, Ohman EM, Braunwald E, Gibson CM, for the TIMI Study Group. Association of Smoking with Improved Myocardial Perfusion and the Angiographic Characterization of Myocardial Tissue Perfusion Following Fibrinolytic Therapy for ST-Elevation Myocardial Infarction, J Am Coll Cardiol, in press.
168. Kirtane AJ, Weisbord A, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Harrington RA, Ohman EM, Roe MT, Braunwald E, and Gibson CM, for the TIMI Study Group. Relation of Impaired TIMI Myocardial Perfusion Grades to Residual Thrombus Following the Restoration of Epicardial Patency in ST-Elevation Myocardial Infarction, Am J Cardiology, in press.
169. Kirtane AJ, Kosmidou I, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, and Gibson CM, for the TIMI Study Group. Association of Culprit Lesion Calcium with Angiographic and Clinical Outcomes in Patients with ST-Elevation Myocardial Infarction Treated with Fibrinolytic Therapy, Am J Cardiology, in press.
Proceedings of Meetings
170.
Cannon
CP, Gibson CM. TIMI Flow Grade and TIMI Frame Count, in The First
International Thrombolytic Collegium, Prognostic Markers for the Management of
Acute Myocardial Infarction, published by Medical Forum, Parsippany NJ, 1997.
171.
Braunwald
E, Gibson CM. New strategies in the management of acute MI: Protecting
the microcirculation. Medical Education Reports, Interviews and Testimony 2000;
2: 20-21.
172.
Gibson
CM. The time dependent
open vasculature hypothesis. Brigham and Women’s Hospital Grand Rounds series,
December 2000.
Review Articles
173.
Gibson
CM,
174.
Gibson CM,
175.
Gibson
CM, Stone PH. How do intracoronary hemodynamics affect the natural history of
coronary atherosclerosis? Choices in Cardiology 1993; 7:333-335.
176.
Gibson CM, Al-Mousa EN. Newer thrombolytic agents. UpToDate in
Internal Medicine 1996-1998; 3:3, CD
177.
Dodge
JT, Gibson CM. Thrombolysis in the elderly. UpToDate in Internal
Medicine 1996-1998; 3:3, CD
178.
Goel
M, Rizzo MJ, McLean C, Ryan K, Dotani I, Marble SJ, Daley WL, Dodge T, Gibson
CM. The Open artery Hypothesis:
Past, Present and Future. Journal of Thrombosis and Thrombolysis 1998;
5:101-112.
179.
180.
Gibson
CM, Moynihan J.
Reocclusion Following Thrombolysis.
UpToDate in Internal Medicine 1997-1998; version 5.3 (CD ROM).
181.
Gibson
CM. Primary angioplasty
versus thrombolysis in acute myocardial infarction: Strengths and
limitations. UpToDate in Internal
Medicine 1998; (CD ROM).
182.
Gibson
CM, Moynihan JL,
Al-Mousa E, Campsey M, Gandhi R, Murphy S, Mattson S, Ryan KA, Mesley R,
Swanson J, Arshad MN, Marble SJ. Glycoprotein IIb/ IIIa Receptor Inhibition in
Interventional Cardiology. Journal of Thrombosis and Thrombolysis1999; 7:
287-301.
183.
Gibson
CM. Treatment for failed
thrombolysis. UpToDate in Internal Medicine 1998; (CD ROM).
184.
Gibson
CM. Newer thrombolytic
agents and combination therapy in acute myocardial infarction. Rev Soc Cardiol
Estado de Sao Paulo 1999; 1: 831.
185.
Michaels
A, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial
infarction: focus on the roles of platelet and inflammatory mediators in the
no-reflow phenomenon. Am J Cardiol 2000; 85: 50B-60B.
186.
Appleby
MA, Michaels AD, Chen M, Gibson CM. The Importance of the TIMI Frame
Count: Implications for Future Trials. Curr Control Trials Cardiovasc Med. 2000;1(1):31-34.
187.
Gibson CM, Marble SJ. Issues in the assessment of
the safety and efficacy of tenecteplase (TNK-tPA). Clin Cardiol. 2001 Sep;24(9):577-84.
188.
Angeja
BG, Gibson CM, Chin R, Canto JG,
Barron HV. Reperfusion in the Elderly.
Drugs and Aging 2001; 18 (8): 587-96.
189.
Appleby
MA, Angeja BG, Dauterman K, Gibson CM.
Angiographic assessment of myocardial perfusion: TIMI myocardial perfusion
(TMP) grading system. Heart 2001 Nov;86(5):485-6.
190.
Gardner
G, Pinto D, Gibson CM. Reperfusion
injury. Up to Date in Internal Medicine, 2002 (CD ROM).
191.
Gibson
CM, Carozza JC, Laham R, Baim DS. Clinical
trials of primary percutaneous coronary intervention in acute myocardial
infarction-I. Up to Date in Internal Medicine, 2002 (CD ROM).
192.
Gibson
CM, Carozza JC, Laham R, Baim DS. Clinical
trials of primary percutaneous coronary intervention in acute myocardial
infarction-II. Up to Date in Internal Medicine, 2002 (CD ROM).
193.
Gibson CM, Mousa E, Levin
T. Characteristics of thrombolytic agents and efficacy in clinical trials-I. Up
to Date in Internal Medicine, 2002 (CD ROM).
194.
Gibson CM, Mousa E, Levin
T. Characteristics of thrombolytic agents and efficacy in clinical
trials-II. Up to Date in Internal Medicine, 2002 (CD
ROM).
195.
Gibson CM, Levin T. Use of
thrombolytic agents in clinical practice-I.
Up to Date in
Internal Medicine, 2002 (CD ROM).
196.
Gibson CM, Levin T. Use of
thrombolytic agents in clinical practice-II.
Up to Date in Internal Medicine, 2002 (CD ROM).
197.
198.
Pinto
DS, Aroesty JM, Reynolds MR,
199.
Dumaine
R, Bigelow B, Gibson CM. Myocardial
reperfusion. Its assessment and its relationship to clinical outcomes. American Heart Hospital Journal, 2003 in
press.
200.
Guerra DR, Gibson CM. Door-to-Balloon Delays with PCI
in Acute Myocardial Infarction. Curr Treat
Options Cardiovasc Med. 2004 Feb;6(1):69-77. 2003.
201.
Gibson CM,
202.
Gibson
CM,
203.
Gibson CM, Levin T. Thrombolytic agents in acute
ST elevation (Q wave) myocardial infarction: Markers of efficacy. Up to Date, CD
204.
Gibson CM. Care
of ST-Segment Elevation Patients: Insights from NRMI. Am Heart Journal
2004, in press.
Book Chapters
205.
Gibson
CM. Profiles in Coronary
Artery Disease in William Grossman and Donald S. Baim, Cardiac Catheterization,
Angiography and Intervention, Fifth edition, Lea and Febiger, 1995, pp.757-762.
206.
Gibson
CM, Stone PH, Pasternak
RC, Sacks FM, for the Harvard Atherosclerosis Reversibility Project Group.
Impact Upon Angiographic Disease Progression Following
Step Drug Therapy in Normolipidemic Patients: Results of the Harvard
Atherosclerosis Reversibility Project (HARP) in Lipid lowering therapy and
progression of coronary atherosclerosis, pp.179-191, 1996 Kluwer Academic
Publishers, Printed in
207.
Gibson
CM. Primary and Rescue
Angioplasty in the Setting of Acute Myocardial Infarction in Randomized Trials
in Cardiovascular Disease, (published as a companion to Braunwald's Heart
Disease), First edition, W.B. Saunders, 1999.
208.
Gibson
CM, Marble SJ. Rizzo MJ,
Ryan K, Goel M. Insights into flow disturbances using the TIMI Frame Count, in
Management of Acute Coronary Syndromes, first edition, 1998.
209.
Goel
M, Sparano A, Moynihan J, Kelley M, Gibson CM. Angioplasty, Stents and
New devices, in Management of Acute Coronary Syndromes, first edition, 1998.
210.
Gibson
CM. Profiles in Coronary
Artery Disease in William Grossman and Donald S. Baim, Cardiac Catheterization,
Angiography and Intervention, Sixth edition, Lea and Febiger, 2000.
211.
Chatterjee
K, Gibson CM. Recognition and Management of Patients with Stable Angina
Pectoris in Eugene Braunwald and Lee Goldman Primary Cardiology, Second
Edition, in press 2001.
212.
Gibson CM, Murphy SA,
Popma JJ. Insights into flow
disturbances using the TIMI Frame Count and TIMI Myocardial Perfusion Grade, in
Management of Acute Coronary Syndromes, second edition, in press 2002.
213.
Singh
K, Gibson CM. Angioplasty, Stents and New devices, in
Management of Acute Coronary Syndromes, second edition 2002, in press.
214.
Popma
JJ, Gibson CM. Quantitative Coronary
Arteriography in Textbook of Interventional Cardiology, Topol EJ, 4th
edition, 2002, in press.
215.
Gibson CM, Sperling R. Management of Anastomotic
Lesions. Treatment Strategies in Interventional Cardiology, Pocket Medicine
Inc.,
216.
Gibson CM, Pinto D. Management of Angulated
Lesions. Treatment Strategies in Interventional Cardiology, Pocket Medicine
Inc.,
217.
Gibson CM, Pinto D. Management of Anticoagulation
in PCI. Treatment Strategies in Interventional Cardiology, Pocket Medicine
Inc.,
218.
Gibson CM, Pinto D. Management of Bifurcation Lesions. Treatment
Strategies in Interventional Cardiology, Pocket Medicine Inc.,
219.
Gibson CM, Tu T. Management of Calcified Lesions.
Treatment Strategies in Interventional Cardiology, Pocket Medicine Inc.,
220.
Gibson CM, Lorenz D. Management of Coronary Spasm.
Treatment Strategies in Interventional Cardiology, Pocket Medicine Inc.,
221.
Gibson CM, Frisch D. Management of the Diabetic
Patient. Treatment Strategies in Interventional Cardiology, Pocket Medicine
Inc.,
222.
Gibson CM, Tu T. Management of Left Main Disease.
Treatment Strategies in Interventional Cardiology, Pocket Medicine Inc.,
223.
Gibson CM, Sperling R. Management of Multivessel
Disease. Treatment Strategies in Interventional Cardiology, Pocket Medicine
Inc.,
224.
Gibson CM, Pinto D. Management of No-Reflow.
Treatment Strategies in Interventional Cardiology, Pocket Medicine Inc.,
225.
Gibson CM, Pinto D. Management of Ostial Lesions.
Treatment Strategies in Interventional Cardiology, Pocket Medicine Inc.,
226.
Gibson CM, Pinto D. Management of Perforation. Treatment Strategies in
Interventional Cardiology, Pocket Medicine Inc.,
227.
Gibson CM, Lorenz D. Primary Percutaneous
Intervention for Acute Myocardial Infarction. Treatment Strategies in
Interventional Cardiology, Pocket Medicine Inc.,
228.
Gibson CM, Frisch D. Management of the PCI Patient
with Renal Failure. Treatment Strategies in Interventional Cardiology, Pocket
Medicine Inc.,
229.
Gibson CM, Sperling R. Management of Thrombotic
Lesions. Treatment Strategies in Interventional Cardiology, Pocket Medicine Inc.,
230.
Gibson CM, Pinto D. Management of the Chronic
Total Occlusion. Treatment Strategies in Interventional Cardiology, Pocket
Medicine Inc.,
231.
Gibson CM, Lorenz D. Management of the PCI Patient
with Unstable Angina. Treatment Strategies in Interventional Cardiology, Pocket
Medicine Inc.,
232.
Nguyen
T, Turakhia MP, Gibson CM.
Management of ST-Elevation Acute Myocardial Infarction in Practical Handbook of Interventional
Cardiology, in press 2003.
Invited Editorials
233.
Gibson
CM. Primary angioplasty
versus thrombolysis. New issues in the
era of glycoprotein 2b3a inhibition and stenting. Annals of Internal Medicine
1999; 130: 841-847.
234.
Gibson
CM. The sundial and the
stopwatch. American Heart Journal, 1999; 138:614-617.
235.
Gibson
CM. A union in
reperfusion: The concept of facilitated PCI. J Am Coll Cardiol 2000; Nov 1;36(5):1497-9.
236.
Angeja
B, Gibson CM. Preserved Coronary Flow Reserve in Viable Myocardium:
Further Evidence for the Microvascular Hypothesis. Am Heart J. 2001 Mar;141(3):329-30.
237.
Gibson CM. Time is myocardium and time is
outcomes. Circulation 2001, Nov 27;104(22):2632-4.
238.
Gibson CM. Has My
Patient Achieved Adequate Myocardial Reperfusion?
Circulation. 2003 Aug 5;108(5):504-7.
239.
Gibson CM. Confusion in reperfusion. J Am Coll Cardiol 2003, in press.
240.
Gibson CM, DeLemos JA, Antman
EM. Time is muscle in
primary PCI: the strength of the evidence grows Eur Heart J. 2004
Jun;25(12):1001-2.
Letters to the Editor
241.
Diminution
in Flow Following Primary Stenting in the INAMI Study. Murphy SA, Gibson CM.
Catheter
Cardiovasc Interv. 2003 Jul;59(3):417.
242.
Gibson
CM. Angiographic
assessment of coronary flow by the TIMI frame counting technique using the
Cordis StabilizerTM marker wire, distributed by Cordis Corporation
(1997).
243.
Goel
M, Gibson CM. References on a wide variety of topics pertaining to
coronary artery blood flow and patency.
Journal of Thrombosis and Thrombolysis 2000; 9:85-93.
244.
Gibson
CM. How to do the TIMI
Frame Count. A demonstration on the
PERFUSE website at www.perfuse.org
245.
Gibson
CM. How to do the TIMI
Myocardial Perfusion Grade. A demonstration on the PERFUSE website at www.perfuse.org
246.
Gibson
CM. TIMI frame count and
TIMI myocardial perfusion grades. New methods to assess coronary reperfusion.
www.chestpainonline.org, Jan 2000.
Abstracts
247.
Gurney
CW, Simmons EL, Gaston EO, Gibson CM,
Langhofer M: Further Studies of
Transient and Sustained Cycling of Erythropoiesis in Mice. Exp. Hematol. 1981;
9:56.
248.
Gibson CM, Gurney CW, Simmons EL, Gaston EO:
Factors Affecting Cyclic Erythropoiesis in Congenitally Anemic Mice. Exp. Hematol.
1982; 10:135.
249.
Gurney
CW, Gibson CM, Simmons EL, Gaston
EO: An Explanation of Cyclic Erythropoiesis in W/Wv and Sl/Sld Mice
Following Low Doses of 89Strontium. Exp. Hematol. 1983; 11:217.
250.
Gibson CM, Stone PH, Pasternak RC, Sandor T, Sacks
FM. Sample Size Requirements to Assess Atherosclerosis Regression Using Quantitative
Angiography. Circulation 1990; 82, suppl. III:517.
251.
Gibson CM, Stone PH, Pasternak RC, Sandor T,
Rosner B, Sacks FM. The Natural History of Coronary Atherosclerosis Using
Quantitative Angiography: Implications for Regression Trials. JACC 1991; 17:231A.
252.
Gibson CM, Stone PH, Pasternak RC, Sandor T,
Rosner B, Sacks FM. Sample Size Considerations in Atherosclerosis Regression
Trials. Presented at the NIH Workshop on Stabilization and Regression of
Atherosclerosis, June 20 - 21, 1991.
253.
Gibson CM, Diaz L, Kandarpa K, Sacks FM, Pasternak
RC, Sandor T, Feldman C, Stone PH. The Relationship of Vessel Wall Shear Stress
to Atherosclerosis Progression. Circulation 1991; 84, supplement II:108.
254.
Carroza
J, Kuntz R, Pomerantz R, Fishman R, Mansour M, Gibson M, Senerchia C, Diver D, Safian R, Baim D. Encouraging Acute
and Long-Term Angiographic and Clinical Outcome of Coronary Stenting: A Large
Single Center Experience. JACC 1991; 19: 48A.
255.
Marcus
E, Gibson M, Gwathmey J. Results of
Frame-by-Frame Curvature Difference Ventriculogram Analysis. JACC 1991; 19:
16A.
256.
Gibson CM, Piana RN,
257.
Gibson CM, Cannon CP, Piana RN, Maher KA, Davis
SF, Breall JA, Davis V, Diver DJ for the TIMI 4 Study Group. Relationship of
Coronary Flow to Myocardial Infarction Size: Two Simple New Methods to
Sub-Classify TIMI Flow Grades. Circulation 1992;86:I-453.
258.
Kuntz
RE, Gibson CM, Gordon PC, Diver DJ.
The Advantage of Continuous Angiographic Endpoints Over
Absolute Luminal Narrowing in the Analysis of Restenosis. Circulation 1992;86:I-122.